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Abstract: 
 
 
Introduction: GBS has a highly diverse clinical course and outcome. Currently 
available literature suggests that despite treatment about 20 % of patients 
remain disabled at one year and about 5 % patients die. These data come from 
clinical trials conducted between 1984 and 2006. Most of these studies included 
severe GBS cases. We conducted a multicentre prospective observational study 
looking at clinical and biological determinants of prognosis of GBS. As part of 
this study, I had an opportunity to analyse the data collected from 15 UK 
centres; looking at clinical and treatment patterns, various outcomes including 
ability to walk at 12 months, pain and quality of life. We also analysed 
Electrophysiological data from our local centre (Glasgow); compared newly 
published electrophysiological diagnostic criteria with existing criteria to 
determine whether serial studies are required for final electrophysiological 
diagnosis. Finally, to identify the patients with poor prognosis early in the 
disease course, we attempted to validate the currently available clinical 
prognostic models. 
 
Method: We conducted a multicentre prospective observational study named 
IGOS (International GBS Outcome Study) with a web-based entry system. It 
aimed to study at least 1000 patients over 3 years. The study included two 
modules: 1) core module which consist of a) acute clinical data collection at 0, 
1, 2, 4 weeks and follow up data at 6 and 12 months b) serum samples 
collection at each clinical data entry point c) electrophysiology studies within 2 
weeks 2) optional modules included additional electrophysiology studies at 4 
weeks, CSF studies and long term outcome data at 2 and 3 years. As the study 
still ongoing, I analysed the data of 122 GBS patients recruited from 15 UK 
centres between May 2012 and Jan 2015. 
 
Results: In our cohort about 20 % patients remained disabled at 1 year, 18 % 
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required mechanical ventilation (MV), 5 % died. Pain continued to remain a 
major disabling symptom in more than half of the patients however unable to 
perform usual activity was the most disabling QoL domain affected at 12 
months and was an important contributing factor affecting quality of life. 
Intravenous immunoglobulin was the most commonly prescribed treatment 
followed by plasma exchange. Immunotherapy was not beneficial in mildly 
affected GBS patients. Currently available electro diagnostic criteria are not 
very sensitive in identifying final EP subtypes and newly published Rajabally’s 
criteria potentially addresses this issue and should be used in clinical practice to 
establish final EP diagnosis. Existing prognostic models EGOS and mEGOS 
performed well in our cohort and showed good discriminatory capacity 
 
Discussion: Despite wider availability of immunotherapy prognosis of GBS 
has not changed in last 20years, which highlights the urgent need of more 
effective treatments in these patients. However new therapy can be expensive 
and can be only beneficial if the patients with poor prognosis are identified 
early in course. This can only be achieved by developing good prognostic 
models. Our results show that existing available models EGOS/MEGOS 
validates well and provides a proof of the concept that prognostic model can be 
used to identify patients with poor prognosis when the treatment is most 
beneficial. GBS continues to remain a clinical diagnosis. While there are 
drawbacks of existing EP criteria, newly developed Rajabally’s criteria are 
sufficient to establish final EP diagnosis. 
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Guillain–Barré syndrome (GBS) is a spectrum of post infectious monophasic 
autoimmune disorders of peripheral nerves with a highly diverse clinical course and 
outcome. It was first described by French neurologists Georges Guillain, Jean-
Alexander Barré and Andre Stroll in 1916.(1) After eradication of poliomyelitis, GBS 
has become the most common cause of acute flaccid paralysis worldwide. A typical 
GBS is characterised by symmetrical ascending weakness with minimal sensory 
symptoms and signs. Several regional clinical variants have been well described. One 
such variant is Miller Fisher Syndrome, a syndrome characterised by ataxia, 
ophthalmoplegia and areflexia, originally described by American neurologist Charles 
Miller Fisher.(2) Other regional variants include Pharyngeal-Cervical-Brachial (PCB) 
weakness and Bickerstaff Brainstem encephalitis (BBE). 
 
 
 
1.1 Historical Perspective: 
 
 
 
The concept of ‘acute paralysis caused by peripheral nervous involvement’ emerged in 
1843, when Robert Graves, during a widespread epidemic, described various cases of 
acute polyneuropathies presenting as acute pain, paresthesia followed by paralysis.(3) 
In 1859, this concept evolved even further, when French physician Jean Baptiste 
Octave Landry de Thezillat described 10 cases of acute ‘ascending’ paralysis and of 
which, some patients also developed respiratory paralysis within 2 weeks of onset of 
symptoms. (4) Two of these 10 patients died and when autopsies performed, no central 
nervous system abnormality found, which led him to conclude that the disease must be 
a peripheral in origin. The disease was originally known as ‘Landry’s paralysis’. In 
1890, Osler published another case series of patients with ascending paralysis and 
respiratory involvement. 
 
In 1916, during the first world war, French neurologists Georges Guillain, Jean-
Alexandre Barré and Andrew Strohl described two cases similar to ‘Landry’s 
paralysis’ in French soldiers, but they resisted calling it ‘Landry’s paralysis’ as they 
thought their cases had better prognosis while Landry’s cases had poor prognosis, 
moreover both of patients had elevated cerebrospinal fluid protein level with normal 
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cell count, a finding later on became one of the very important characteristics of the 
disease. Interestingly, Strohl’s name was dropped in subsequent publications and 
disease was widely referred as “Guillain–Barré syndrome”. In 1949, based on nerve 
biopsy reports Haymaker and Kernohan provided first ever pathological proof of 
underlying demyelination and this coupled with further report by Waksman and Adam 
describing animal models of extrinsic allergic neuritis led to the notion that GBS was a 
demyelinating disorder of peripheral nerves. (5,6) However this view was challenged 
by Feasby et al when they published the first report of “Acute Axonal GBS” in 
1986.(7) McKhann et al later on substantiated this view and described a case series of 
Chinese GBS patients with predominant axonal degeneration as an underlying 
pathology. Clinically and pathologically, GBS now widely considered being a 
spectrum of post infectious polyneuritis. 
 
1.2 Epidemiology: 
 
Most epidemiological studies in GBS literature have been performed in Europe and 
North America. A recent review of all published epidemiological studies performed 
worldwide showed incidence of GBS were higher in prospective studies compared to 
retrospective studies, which probably represents the true incidence of GBS in western 
world.(8) Most prospective studies, showed the incidence rates of 1.11 to 1.66 cases 
per 100000 populations per year. Moreover most studies being performed using 
NINDS criteria for the diagnosis and therefore did not include MFS cases and none of 
these studies has systematically studied clinical and electrophysiological subtypes and 
therefore it is difficult to determine true incidence of each clinical GBS subtype. 
 
Unfortunately there is no epidemiological data available from developing world. Lack 
of appropriate research infrastructure and resources to perform such studies remain 
major challenges in developing world. Since most developing countries have now 
successfully eradicated Poliomyelitis, GBS is emerging as a major cause of acute 
flaccid paralysis (AFP). In a recent study Islam et al systematically analysed the 
surveillance data on reported AFP cases from Bangladesh and have shown that 
although Bangladesh has been successful in eradicating poliomyelitis since 2000, non-
polio AFP cases are continue to occur, with the incidence rate of 3.25 per 100,000 
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children less than 15 year of age and a great proportion of these non -polio AFP cases 
are diagnosed as GBS with crude incidence rates of GBS in children varied from 1.5 
to 5 per 100,000 per year.(9) Thus the study demonstrated that, GBS rates are at least 
2 to 3 times higher than what has been reported in Americas and Europe, and the 
burden of GBS in developing country could be much higher than previously thought. 
 
The incidence of MFS has been reported to be considerably higher in eastern world 
with 19 % in Taiwan and 26 % in Japan.(10,11)  Incidence of even rare variant, 
Bickerstaff Brainstem Encephalitis (BBE) has not been studied in western world, but 
one such study from Japan has reported the incidence of BBE is about 0.07 per 
100000.(12) 
 
1.3 Clinical Spectrum of GBS: 
 
Clinically, GBS can be divided into two broad categories: Typical GBS and Variants. 
While typical GBS has been widely described as predominant motor syndrome with 
minimal sensory involvement, recognition of pure motor form of GBS in china has 
given a very interesting dimension to this area. As further research continue in this 
area description of other disease variants continued to emerge. Understanding of 
various clinical subtypes is very important in order to get better insight of underlying 
immune pathogenesis, pathophysiology and prognosis of GBS. 
 
 
 
1.3.1 Typical GBS: 
 
 
A typical GBS is a monophasic illness characterised by rapidly progressive 
symmetrical ascending weakness with minimum clinical sensory symptoms, however 
involvement of sensory fibre on electrophysiology is very frequent. Clinically the 
disease course can be broadly divided into four stages 1) stage of invasion 2) stage of 
progression 3) Plateau stage and 4) stage of recovery. 
 
1. Stage of invasion: This is the phase when the initial inflammatory process 
start to affect the peripheral nerves and often a typical GBS starts with sensory 
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symptom. Inflammatory involvement of nerve roots and giant 1a sensory 
afferent fibre involvement lead to back pain and areflexia. Radicular pain can 
be a presenting feature. 
2. Stage of disease progression: As the disease progresses further, patient 
typically develops ascending limb weakness. Hip flexors are commonly 
affected and suggest underlying proximal nerve root Involvement. In about 25 
% of cases, involvement of phrenic nerve leads to respiratory muscle paralysis 
and requirement of mechanical ventilation. Cranial nerve involvement leads to 
diplopia and dysphagia requiring nasogastric feeding. Autonomic disturbances 
have been reported 65% cases. About half of the patients develop Syndrome 
of Inappropriate ADH secretion (SIADH). Majority of patients reach nadir 
within 4 weeks of symptom onset after that they enter into a plateau phase. 
3. Plateau Phase: This phase is characterised by stabilisation of muscle weakness 
and can last up to 4 weeks. 
4. Stage of recovery: This is the phase where the muscle weakness begins to 
improve and often one group of muscle improves earlier than others. It 
continues for 6 months to 2 years. As the recovery in muscle weakness 
continues painful paresthesia and fatigue can become prominent symptoms 
and often lead to significant long-term disability. 
 
1.3.2 Clinical Variants: 
 
 
1. Pure Motor GBS: Although a typical GBS has very minimal sensory 
involvement, clinically and electrophysiologically, pure motor GBS cases 
without any sensory involvement have been reported especially in Southeast 
Asia. This form of GBS is characterised by acute onset of symmetrical limb, 
facial and oropharyngeal muscle weakness without any sensory loss. It was 
first described in children, infected with C.Jejuni in northern china. (13) 
Although most patients have absent deep tendon reflexes, small proportion 
patients have hyperreflexia. CSF typically shows elevated protein and normal 
cell count. Electrophysiology typically shows selective involvement of motor 
fibres without any sensory fibre involvement. Most studies show typical low 
CMAPs suggestive of underlying motor axonal damage however sometimes 
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features of demyelination can be seen. Needle EMG shows diffuse 
denervation. Pattern of recovery can be variable, while some patients recover 
rapidly with complete reversal of EPS abnormality, others follow long 
protected course in which recovery process is complicated by on-going axonal 
degeneration on EMG. 
2. Sensory GBS: Recently Uncini and Yuki have described a series of patients 
who presented with acute pure sensory symptoms and signs reaching their 
nadir within 6 weeks. (14) They suggested a new terminology “sensory GBS” 
based on the size of sensory fibres involved and the possible site of primary 
damage. They attempted to classify sensory GBS in to three different 
subgroups a) Acute sensory demyelinating polyneuropathy b) Acute large 
fibre axonopathy-ganglionopathy c) Acute small fibre neuronoathy-
ganglionopathy. 
(i) Acute sensory demyelinating polyneuropathy: This terminology was 
proposed for a subgroup ofpatients who present with acute sensory 
symptoms and signs with areflexia. Electrophysiology showed 
demyelinating features in both motor and sensory nerves, however no 
conduction blocks demonstrated in motor nerves. 
(ii) Acute sensory large fibre axonopathy-ganglionopathy: This 
encompasses two different clinical entities a) ataxic GBS and b) acute 
sensory ataxic neuropathy. Richter first proposed “Acute ataxic GBS” 
term in 1962. He described a case with acute cerebellar type ataxia and 
areflexia without proprioceptive sensory loss and ophthalmoplegia. 
Later on, few more cases have been described in the literature with 
similar presentation. Electrophysiology typically does not show any 
abnormality. There has been an ongoing debate as to origin of the 
ataxia in these cases. Some propose that ataxia is centrally mediated 
while the others think that it is an incomplete form of miller fisher 
syndrome without ophthalmoplegia and ataxia is due to GQ1b antibody 
mediated damage to group 1a afferents along their path from muscle 
spindles to spinal cord, which may explain normal electrophysiological 
finding as routine sensory nerve conduction studies do not examine 
group 1a fibres. (15–17) Acute sensory ataxic neuropathy term has been 
proposed to describe patients with acute sensory symptoms and ataxia 
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with loss of proprioception, areflexia and positive Romberg sign. EPS 
typically show selective involvement of sensory nerves with absent or 
reduced Sensory nerve action potentials. In some patients with ASAN, 
recovery may be incomplete leading to permanent ataxia indicates that 
the site of the lesion in this group of patients may be the primary 
sensory neurones, while in some patients there is rapid clinical recovery 
associated with reversal of electrophysiological findings suggest that 
the lesion may be in distal sensory nerve axons. Overall authors 
proposed that with selective afferent involvement of 1a afferent fibres, 
patients present with cerebellar type ataxia and normal EPS and with 
more confluent involvement of sensory fibres, patient present with 
sensory ataxia and abnormal EPS findings. 
(iii) Acute small fibre neuropathy-ganglionopathy: In the same report 
Uncini and Yuki described 10patients who presented with acute onset 
burning pain and numbness without ataxia and proprioceptive 
involvement. CSF showed cytoalbumin dissociation in 7 patients. 
(18,19) All patients reached their nadir within 6 weeks. In a few 
patients symptoms and signs were in non-length dependent fashion 
suggestive small fibre ganglionic involvement. Although the nerve 
conduction studies were normal, all the patients had abnormal thermal 
threshold studies. Authors suggested that these patients had acute small 
fibre neuropathy-ganglionopathy. 
 
3 Miller Fisher Syndrome: Miller Fisher syndrome (MFS) is a clinical 
variant of GBS and characterised by clinical a triad of ophthalmoplegia, 
ataxia and areflexia. Fisher first reported the syndrome in1956. (2) Apart 
from classical triad, patients also present with pupillary abnormalities, 
ptosis, bulbar and facial palsy. Occasionally patient presents with only 
limited form of MFS, with ophthalmoplegia or isolated bulbar symptoms 
only. MFS often overlap with classic GBS and patients go on to develop 
limb and respiratory weakness. 
4 Bickerstaff Brainstem encephalitis: In 1951 Bickerstaff and Cloake first 
published report of three cases with asymmetric ophthalmoplegia, ataxia 
and impaired consciousness. (20) They used the term “mesencephalitis” to 
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describe the syndrome, the term subsequently changed to “Bickerstaff 
Brainstem encephalitis”. All these patients had preceding infection and CSF 
cytoalbumin dissociation and had benign outcome. Based on radiological 
and pathological findings, they argued that these patients had CNS 
pathology. However, some others argued that some of the cases described 
by these authors were typical of MFS and considered BBE as a variant of 
MFS, citing the presence of antecedent infection (92%), cytoalbumin 
dissociation (59 %) and presence of anti-GQ1b antibodies (66%) as features 
common to both disorders. (12) 
5 PCB: This regional variant is characterised by rapidly progressive 
oropharyngeal and cervico-brachial weakness and upper limb areflexia. 
Some patients with PCB variant have associated ophthalmoplegia and 
ataxia and therefore it is widely considered as a variant of fisher syndrome. 
Most patients have antibodies against GT1a and these antibodies often cross 
react with GQ1b. 
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1.4 Pathology and immune pathogenesis: 
 
 
 
Pathologically, GBS can be classified into two different forms; A) demyelinating and 
B) axonal form. This classification was based on initial autopsy reports from GBS 
patients, and since the autopsies are rarely performed nowadays, electrophysiological 
markers is used to classify GBS in to demyelinating or axonal variants. Clinically, it is 
difficult to differentiate between these two variants, as motor, sensory and autonomic 
symptoms are common to both pathologies. 
 
1.4.1 Pathology in Acute Inflammatory Demyelinating Polyneuropathy 
(AIDP) 
 
 
Landry’s original report published in 1859 was instrumental in setting the direction for 
further pathological studies involving peripheral nerves in GBS. (4) In his autopsy 
report, he noticed that patients did not have any pathology in spinal cord and brain, 
concluding that pathology most likely to be in peripheral nerves of these patients. In 
their clinicopathological report of 50 fatal GBS cases, Haymaker and Kernohan in 
1949 proposed that the nerve root oedema with subsequent myelin breakdown and 
lymphocytic infiltration was a primary pathological process in GBS. (5) Interestingly 
around the same time, in 1955, Waksman and Adams developed first experimental 
allergic neuritis (EAN) animal models by immunising Lewis rat with whole peripheral 
nerve myelin and complete Freund's adjuvant.(6) The pathological findings in these 
animals showed perineural oedema with lymphocytic infiltration and macrophage 
mediated demyelination. Similarly, in 1969, Asbury and his colleagues in their report 
of 19 GBS autopsies, found perivascular mononuclear infiltrates and segmental 
demyelination which led many researchers to believe that EAN was a counterpart of 
human GBS and demyelination was a primary pathology in GBS. (21) 
 
Further pathological studies showed two patterns of demyelination; in the first pattern 
there is vesicular myelin degeneration causing soap bubble appearance on microscope 
followed by macrophage invasion into the myelin as scavenger cells, this was 
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associated with complement and immunoglobulin activation; the second pattern 
showed macrophage entry through the node or internodes in apparently normal nerve 
cell fibre. (22,23) Although pathologically the demyelinating process can be very 
widespread along the nerve fibre, it predominantly affects the proximal nerve roots and 
distal intramuscular nerve terminals where the blood nerve barrier is deficient. 
Electrophysiologically this is evident by absent F waves and prolonged distal motor 
latency. 
 
 
 
 
 
 
 
 
 
Figure 1-1 GBS Pathology 
From Hafer mako et al, Different degree of inflammatory response in sequential manner. 
A) Day 3 occasional demyelination B) on day 7 foamy microphages (m) C) advanced 
perivascular demyelination D) complete demyelination 
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1.4.2 Pathology in Axonal GBS: 
 
 
In 1986, Feasby at et described 5 GBS cases with inexcitable nerves and autopsy 
showing widespread axonal degeneration without any evidence of demyelination. (7) 
They proposed that primary pathology in these cases was axonal degeneration. 
However this concept remained controversial until 1993, when McKhann and his 
colleagues published a first comprehensive autopsy reports of Chinese GBS patients 
showing wallarian type degeneration involving motor fibres without any 
demyelination in these patients and derived the conclusion that pathologically axonal 
GBS is a distinctive syndrome distinguishable from poliomyelitis and AIDP. (24) 
 
Although the initial pathological reports showed predominant motor fibre 
involvement, a further study showed that these changes were not fibre specific, and 
depending on the involvement of sensory or motor fibres clinical phenotype varies. In 
AMAN these changes are seen predominantly in motor fibres and in AMSAN, changes 
seen in both motor as well as sensory fibres. 
 
Antibody mediated attack to axolemmal membrane leads to either reversible 
conduction failure or completely irreversible axonal injury, which can be explained 
clinically by two different types of outcomes in axonal GBS patients. 
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1.4.3 Immune-pathogenesis: T cell or B cell? 
 
 
Understanding of underlying immunopathogenesis is of paramount importance in 
selecting the correct therapeutic approaches for any immunological disorder. As far as 
GBS is concern, whether it is a T cell or B cell mediated disorder has been 
continuously debated. In recent years significant progress has been made in our 
understanding of this spectrum of disorders. While immunopathogenesis in Axonal 
GBS and FS has been very well understood, the underlying mechanism of AIDP 
remains elusive. 
 
Traditionally, GBS was thought to be a T cell mediated disorder and this was based on 
close resemblance of pathological findings from human autopsy from GBS patients 
and T cell mediated “experimental allergic neuritis” (EAN) animal models. (6) These 
T cell mediated EAN animal model were developed by injecting myelin protein 
components. Therefore, identification of antigenic myelin protein components has 
remained a major focus of the research in this field for long time. Unfortunately, 
research in this field has failed to identify any myelin protein related antibodies so far. 
 
The concept of ‘T cell mediated immune damage’ has been challenged recently and 
there is growing body of evidence to suggest that GBS, at least in some forms, is a B 
cell or antibody mediated disorder, in which complement fixing IgG1/3 subclass anti-
ganglioside antibodies play a major role. Thus, the focus of research has shifted from 
myelin proteins to Schwann cell and axolemmal membrane glycolipid molecules. (25) 
 
Interestingly, identification of pathogenic role of anti glycolipid antibodies (AGA) is 
not a new concept, but it certainly has come round the circle after it being ignored for 
about 20 years. Ilyas et al. had first identified AGA back in 1988, and in fact 
glycoprotein induced EAN animal models have been described even before 1988, first 
by Nagai et al in 1976 and then by Saida et al in 1979. (26–28) The first significant 
breakthrough in this area was the identification of anti GQ1b antibody in MFS; a GBS 
variant, by Chiba and Kusunoki in 1992.(29) This was followed by the development of 
anti GD1b associated ataxic neuropathy rabbit models by Kusunoki et al in 1996 and 
anti GM1 antibody-associated rabbit models of axonal motor neuropathy by Yuki et al 
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in 2001. (30,31) These studies have compelled the researchers to refocus on anti-
glycolipid antibodies and their role in development of some forms of GBS. Further 
studies have shown that various anti-glycolipid antibodies have been associated with 
specific forms of GBS. Anti GM1, anti GD1a, anti GM1b and anti GalNAcGD1a are 
associated with axonal GBS variants and anti Gq1b, GT1a and GD3 GD1b have been 
associated with MFS and chronic ataxic neuropathy. (25) 
1.4.4 Ganglioside Structure and mechanism of injury: 
 
 
Gangliosides, also a subtype of glycospingolipids, are heterogeneous molecules 
composed of a ceramide, linked to one or more hexose sugar molecules and sialic acid. 
(32) The carbohydrate portion consists of variable backbone chain of neutral sugar 
linked to negatively charged sialic acid molecules, which defines ganglioside as a 
distinct subtype of GSL. There are more than 200 different gangliosides present in the 
body and the nomenclature is according to Svennerholm classification, in which GXyz 
represents G as ganglioside, X is a number representing the number of sialic acid 
molecule, y represent the number indicating the length of the neutral sugar and z 
indicates the isomeric form. (33) Gangliosides are present throughout the body; 
however they are highly enriched in nervous system and compose of 10-20 % of the 
total lipid of the outer neuronal membrane layer, which is ten times more compared to 
non-neural tissues. (34) This suggests their specific role in nervous system. The 
hydrophobic ceramide structure is immersed in the lipid membrane the hydrophilic 
sugar molecules are exposed outside the membrane, which may act as antigenic 
targets. Gangliosides are biosynthesised in the Golgi complex by sequential action of 
GalNAc- transferase enzyme. Gangliosides are concentrated in small dynamic 
membrane “rafts’, which plays an important role in cell signalling pathways.(35) 
Different nervous tissues have different expression of gangliosides, which may be 
responsible for different disease phenotypes. For example; GQ1b and GT1a are 
abundant in human extra ocular muscles compared to axial and limb muscles similarly 
GM1 gangliosides are relatively highly expressed in ventral nerve root compared to 
dorsal root ganglia, giving district phenotypic variation. Experimental studies indicate 
that any injury to nervous system alters the biosynthesis of complex gangliosides and 
as the regenerating axon express complex gangliosides it may also affect the axonal 
regeneration and overall disease outcome. (36) 
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Figure 1-2 Glycolipid targets for neuropathy-associated autoantibodies.  
Gal = galactose; GalNAc = N-acetylgalactosamine; Glc = glucose; GlcNAc = N-acetylglucosamine; NeuNAc 
= N-acetylneuraminic acid; GlcUA = glucuronic acid; Cer = ceramide; LM1 = SPG, sialosylparagloboside; 
Hex-LM1 = SLPG, sialosyllactosaminyl- paragloboside; SGPG = sulfated glucuronyl paragloboside; SGLPG = 
sulfated glucuronyl lactosaminyl paragloboside. 
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1.4.5 Molecular mimicry: 
 
 
Post infectious molecular mimicry has been widely described as underlying 
mechanism for Axonal GBS and FS. 
 
In order to satisfy molecular mimicry, the disease must fulfil four criteria. 
 
1) Strong epidemiological evidence between the disease and infection: In context 
of GBS, the possible association between GBS and infection was known long ago, but 
the foundation for molecular mimicry theory was laid by various observational studies 
performed by Rees et al in 1993 and 1995, which provided strong evidence for 
association between C. jejuni infections and GBS. (37–39) 
 
2) Identification of pathogenic antibodies: Evidence related to possible pathogenic 
role of anti ganglioside antibodies in GBS started to emerge from an interesting 
observation from some European countries and north America, showing that some 
patients developed GBS after administration of ganglioside injections for non specific 
pain syndrome. (40, 41) Around the same time, Ilyas et al published the first report 
showing anti ganglioside antibodies in GBS patients. (42) Encouraged with these 
findings researchers started looking for AGA in GBS patient sera. Nobile Orazio et al 
found very high titres of anti GM1 antibodies in GBS patients. (43) Closing the gap, 
Japanese researchers started studying various strains of C Jejuni in GBS sera and 
showed that Penner 19 strain was the most common strain associated with GBS. (44) 
 
3) Identification of microbial mimicry of target antigen: Evidence for this came 
from a study performed by Yuki et al showing that axonal GBS results from cross 
reactivity between bacterial wall lipopolysaccharide and peripheral nerve components 
namely ganglioside.(44) The same group had further shown that bacterial LPS that 
generates immune response in GBS and FS patients shares structural similarity with 
GM1 and GQ1b gangliosides. Anti GM1 and anti GD1 antibodies have been shown to 
be reacting with LPS of few more C Jejuni strains. 
 
4) Reproduction of disease in animal: Evidence in support of this theory came 
from two separate studies showing a) development of AGA and AMAN in animals 
immunised with C. Jejuni LPS b) development of AGA and AMAN in animal models 
immunised with bovine brain gangliosides or GM1. (45) 
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Thus, above studies provided conclusive evidence that shared antigenic determinants 
between peripheral nerve fibres components and infective organisms like 
Campylobacter Jejuni (C.Jejuni) is responsible for molecular mimicry at least in 
AMAN cases. Antigenic stimulation derived from infective organisms generates 
antibody response, which in turn produce antibody-mediated damage to peripheral 
nerve. In most cases the shared antigenic determinants are gangliosides, however 
recent reports suggest that besides gangliosides, some axonal anchoring proteins may 
be the targets. 
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1.5 Diagnosis of GBS and diagnostic challenges: 
 
 
 
GBS essentially remains a clinical diagnosis. CSF and EPS, when abnormal help aid 
the diagnosis however one of the major issues with these diagnostic markers is that both 
CSF and EPS can be normal especially in the early course of the disease. Identification 
of early diagnostic markers has remained a major challenge to the researchers. Early 
diagnosis of GBS is very important as it might influence the treatment and help guide 
better monitoring of GBS patients, especially in acute phase. In order to correctly 
identify GBS spectrum disorder both for research and epidemiological studies, various 
diagnostic criteria have been described. In this section I have discussed the 
development of various criteria and current issues related to these criteria. 
 
1.5.1 Development of Diagnostic Criteria: 
 
After its first description in 1916, the term GBS was loosely applied to describe any 
form of acute polyneuropathies presented with acute flaccid paralysis. In 1960, Osler 
and Sidell, suggested that AFP cases with severe sensory involvement and sphincter 
disturbance should not be included and proposed a clinical criteria and suggested that 
the term ‘GBS’ should only be used to describe a relatively uniform group of disorder. 
(46) However 1966, McFarland and colleagues challenged this view and suggested that 
GBS is complex disorder the criteria proposed by Osler and Sidell was too narrow to 
include all clinical subtype, a view most researchers agree with nowadays. (47) 
 
Further impetus to develop diagnostic criteria came from Centre of Disease Control 
(CDC), USA. This happened on the background of identification of thousands of GBS 
cases following administration of Swine flu vaccine in USA, which resulted in 
multimillion dollar lawsuits on federal government. In order to identify correct GBS 
cases US government and CDC, required an effective surveillance programme and as a 
part of this program CDC urged national Institute of Neurological and Communicable 
Disease (NINCD now NINDS) to developed a clinical criteria for GBS. In 1978 a panel 
of experts proposed diagnostic criteria based on clinical, laboratory and 
electrophysiological features. (48) As per these criteria, GBS can be diagnosed on 
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clinical ground only if a typical symmetrical motor weakness is present along with 
generalized areflexia. In an atypical case laboratory features such as raised CSF protein 
with normal cell counts and EPS features can aid the diagnosis. This criterion was 
developed for neurologist and non-neurologists physicians for the surveillance purpose 
and therefore GBS variants were not included in this criterion. 
 
In 1990, Asbury and Cornblath modified NINDS criteria and proposed other criteria; 
this time they proposed specific EP parameters for demyelination. (49)These criteria 
have been extensively used for diagnostic work up and also in the research settings. 
 
In 2009, the Brighton GBS working group made further such attempts in response to 
study the association of H1N1 vaccine and GBS. (50) The purpose of the criteria was to 
design a practical, sensitive and reasonably specific tool to identify most GBS cases, 
post immunisation. As per these, criteria GBS patients were divided into four different 
categories depending on the diagnostic certainty. Level 1; represented highest degree of 
certainty and included clinical features of bilateral flaccid weakness, areflexia and 
monophasic course and laboratory features of cytoalbumin dissociation and abnormal 
EPS. Level 2; represented the same clinical features as Level 1 but the presence of only 
one of the laboratory features. Level 3; represented only clinical features and level 4; 
represented the least diagnostic certainty based availability of any of the clinical and 
laboratory features in absence of any other diagnostic possibility. Recently Fokke at el 
performed an analysis of Dutch cohort 494 GBS patients from four different clinical 
trials and tried to classify them as per Brighton criteria. (51) The study showed that 
only 41 % patients met level 1 criteria, 36 % of patients met level 2 criteria, 3 % of the 
patients met level 3 and about 22 %of the patients met level 4 criteria. Of those who did 
not meet Level 1 criteria, about 25 % of patients did so due to normal CSF examination, 
3 % of cases had progressive course more than 4 weeks and about 5 % cases did not 
have monophasic course. This study highlights the underlying clinical heterogeneity of 
the disease. 
 
 
 
 
33 
 
1.5.2 Anti Ganglioside antibodies- A new diagnostic marker of GBS? 
 
 
Both glycoproteins and glycolipids have been identified as putative antibody targets for 
GBS. Of all these putative antigens, gangliosides have generated very much interest 
over past two decades. The term gangliosides refers to the large family of 
glycospingolipids that contains sialic acid linked to the oligosaccharide core, 
synthesised through addition of monosaccharides in a stepwise fashion by 
glycosyltransferases and sialyltransferases. (25) Gangliosides are present throughout 
the body but are highly concentrated in the nervous system. Auto antibodies to various 
gangliosides are present in up to 60% of GBS cases in acute phase.(52) While this 
observation does not provide the proof of their pathogenicity, the strength of this 
association has generated a considerable interest in this field of research. 
 
1.5.2.1 GBS subtypes and associated antibodies: 
 
 
AMAN:IgG antibodies targeted against GM1, GD1a, GalNAc GD1a and GM1b 
gangliosides are frequentlyseen in patients with AMAN. In a recent joint Japanese-
Italian study 66% of AMAN patients were positive for the antibodies against any of 
these four gangliosides. (53) Interestingly, in the same study about 30% of anti 
ganglioside positive patients who were originally classified as Acute Inflammatory 
Demyelinating polyneuropathy (AIDP) showed electrophysiological pattern consistent 
with AMAN on repeat examination at 3-6 weeks time. Taking this finding into 
consideration about 83% of AMAN patients had one of these four anti ganglioside 
antibodies. Thus testing for these antibodies may help in identifying motor axonal 
subtype of GBS. However,  IgG anti GM1 antibodies are not specific to axonal variant 
of GBS and can also be found in patients with AIDP and chronic inflammatory 
neuropathies. (54) 
 
AIDP:Unlike AMAN, association between auto antibodies and AIDP is not very clear 
and consistent. Occasionally serum auto antibodies against GM1, GM2, GM3, GD3, 
GT3 and galactocerebroside are found in AIDP. Antibodies against peripheral nerve 
myelin specific glycolipids such as LM1, Hex- LM1 and SGPG have also been found in 
various studies with very modest specificity. (55–57) In a recent study, Kuwahara et al 
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have shown that about 12% of GBS patients have antibodies against LM1. 
 
MFS: A clear and constant association exist between anti GQ1b/GT1a and miller fisher 
syndrome. Anti GQ1bIgG antibodies are present in more than 90% of patients with 
MFS with high level of specificity. (25) Almost all anti GQ1b antibodies cross-react 
with the structurally similar ganglioside GT1a. (29) Some MFS sera also react to GD3 
and GD1b. (58) 
 
BBE: Because of the similarity in clinical presentation and identification of the 
common autoantibodies, antecedent infection, neuroimaging and neurophysiological 
findings BBE is now considered a variant of MFS with some central nervous 
involvement. Serum IgG Antibodies against GQ1b and GT1a gangliosides are found in 
68% and 60% of BBE patients respectively. (12) 
 
Ataxic GBS: Some patients with GBS present with acute ataxia without any limb 
weakness and ophthalmoplegia. IgG antibodies against GQ1b and GD1b gangliosides 
are found in some patients with ataxic GBS. (59) In a recent study Kaida et al. 
investigated the antibody reactivities of anti GD1b IgG positive sera against various 
GD1b containing complexes in GBS patients with and without ataxia. The study 
showed that reactivities of anti GD1b IgG were significantly inhibited by addition of 
other gangliosides in ataxic GBS patients indicating that antibodies highly specific for 
GD1b are strongly associated with ataxia in GBS. (60) This study further support the 
hypothesis that complex lipid environment in nerve membrane could affect the 
accessibility of anti ganglioside antibodies. 
 
Antibodies against Ganglioside complexes: 
 
 
Since their first report in 2004 of anti GSC antibodies in GBS patients Kaida et al have 
subsequently shown that about 17% of GBS patients have antibodies against various 
gangliosides complexes and some of the GSC antibodies are associated with severe 
disability. (61,62) In a recent study, Kuwahara et al has shown that about 7% of the 
GBS patients had antibodies to LM1/GM1 complex and majority of these patients were 
classified to have AIDP on electrodiagnostic studies. (55) Antibodies against 
ganglioside complexes have also been reported in acute motor neuropathy. In a study 
35 
 
Kaida et al found IgG antibodies against GM1/GalNAc-GD1 complex are found in 
patients with acute pure motor neuropathy, characterised by early conduction block 
(CB) at intermediate segments, infrequent sensory and cranial nerves involvement and 
overall good recovery.(63) However there is an ongoing debate whether AMN with CB 
should be considered an AIDP or AMAN. 
 
New non-glycolipid antigenic targets in GBS: 
 
 
Nodal conduction failure plays an important part in GBS pathology however the precise 
mechanism leading to conduction failure has not been very well elucidated. Disruption 
of nodal sodium channel (Nav) cluster has been reported in both AIDP and AMAN and 
therefore lately the focus has been shifted to nodal proteins as target antigens in GBS. 
Languor et al studied the early changes in two animal models of AIDP and in one 
model they demonstrated that NF186 and gliomedin were selectively affected before 
the onset of demyelination and they were associated with serum antibodies against 
neurofascin and gliomedin and disruption of the Nav channels.(64) 
 
 
Pruss et al investigated sera from 52 GBS patients and 44 healthy controls for 
antibodies against two nodal proteins, neurofascin and contactin and found that serum 
neurofascin IgG antibodies were significantly elevated in GBS patients compared to 
normal controls. (65) Thus, antibody screening against various gangliosides and nodal 
proteins can play an important role in early diagnosis of GBS and can be used as early 
diagnostic markers. 
 
However this area of research has various limitations. 1) Historically researchers have 
tried to identify antibodies against a group of antigenic target gangliosides, with a 
concept that a single electrophysiological study is suffice to classify GBS either in to 
AMAN or AIDP. Recent studies have clearly challenged this concept and we now 
know that in GBS, EPS phenotype changes in first few weeks of disease onset. 2) Most 
electrophysiological and serological correlation studies have been performed using only 
a single EPS and therefore raises an important question about the validity of these 
correlations 3) further complexity in this field has been added by the discovery of 
ganglioside complex antibodies. Screening more than 200 ganglioside and their 
complexes is beyond the scope of currently available immunological methods such as 
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ELISA, and therefore newer techniques such as high throughput combinatorial 
microarray has been developed. 
 
1.6 Treatments: 
 
 
 
Treatment of GBS is usually supportive and broad-spectrum immunotherapy. There are 
no specific targeted treatments available yet. In this section various immunomodulatory 
therapies have been discussed. 
 
1.6.1 Corticosteroids: 
 
 
Based on animal models of allergic neuritis, initially, GBS was thought to be a cell 
mediated disorder analogue to experimental allergic encephalomyelitis (EAE). Since 
corticosteroids were effective in treatment of EAE models, it had been used for the 
treatment of GBS for many years with a little success. Most reports were based on 
either anecdotal reports or retrospective studies giving conflicting results. In 1978 RAC 
Hughes et al conducted the first randomised controlled trial of 40 patients comparing 
the efficacy of prednisolone with no treatment. (66) Twenty one patients in treatment 
arm were treated with prednisolone 60 mg for a week, 40 mg for a four days, and then 
30 mg for three days and 19 patient in control arm did not receive any treatment. The 
primary outcome; an average improvement in a six-point disability scale at one, three 
and twelve month was considered. Although mortality rates were the same in both the 
groups, the trial showed that steroid treatment was not effective and in fact had 
detrimental effect on the outcome. About 20 % patients remained significantly disabled 
at the end of 1 year. 
 
Since then two large multi centre double blind trials have been conducted. The first trial 
of 242 patients, treatment arm received high dose intravenous methyl prednisolone 500 
mg daily for 5 days and control arm received placebo infusion. The results did not show 
any statistically significant difference in mean improvement in disability grade after 4 
weeks and 3 months, reduction in duration of artificial ventilation and ability to walk 
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unaided. (67) 
 
In 2004 Van Koningsveld et al conducted another multi centre study with 225 patients 
to assess the effect of methyl prednisolone combined with Intravenous Immunoglobulin 
(IVIG) vs. IVIG alone. This study did not show any significant difference in the 
outcome. (68) 
 
Thus the above studies showed no evidence of beneficial effect of steroid on GBS 
outcome and therefore steroids have no role in GBS treatment. 
 
 
 
1.6.2. Plasma Exchange: 
 
 
In 1978, Brettle et al published the first report of beneficial effect of plasma exchange 
(PE) in GBS. (69) Encouraged by this report and subsequent anecdotal reports showing 
the efficacy of plasma exchange in GBS, Greenwood et al conducted the first 
randomised placebo controlled trial in 1984. (70) This study did not show any 
beneficial effect of PE on GBS outcome, however in the same year, Osterman et al 
published another study with 38 patients comparing PE with supportive care, showed 
that 77 % patients who received PE recovered by more than one functional grade at 4 
weeks as compared with only 30 % in control group with only supportive care.(71) 
Subsequently various studies, including one large multi centre study of 220 patients 
comparing PE with supportive care conducted by French cooperative group on PE in 
GBS showed significant improvement in both primary and secondary outcome 
measures including the rate of improvement in disability grade, median time to recover 
independent walking and disability rates at 1 year. (72) This group also showed that 
four sessions of plasma exchanges were better than two and effect of six session of PE 
was similar to four sessions. As a result of these studies PE was widely accepted as first 
line therapy in patients with GBS. 
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1.6.3. Intravenous Immunoglobulin: 
 
 
Initial report of Imbach and colleagues showing beneficial effect of IVIG in patients 
with immune thrombocytopenia, paved way for its use in other inflammatory 
conditions. (73) Encouraged by this, and subsequent observations that patients with 
CIDP showing beneficial effect of fresh frozen plasma, in 1988 Kleyweg et al 
conducted the first pilot study of eight GBS patients treated with intravenous gamma 
globulin showing beneficial effects in some patients. (74) The same group in 1992 
conducted a randomised controlled trial 150 patients comparing IVIG with PE. (75) 
The results showed that after 4 weeks about 53 % patients improved by one grade on 
GBS disability scale compared to 34 % in PE group, and median time to improve by 
one functional disability grade was significantly shorter in IVIG group (27 days with 
IVIG and 41 days with PE). Although the result of this trial showed slight superiority of 
IVIG over the PE, subsequent study showed similar efficacy. (81) Since then due to 
ease in administration and relatively few complications involved with IVIG, it has now 
become the first line treatment in GBS. 
 
 
 
1.6.4. Newer treatments: 
 
 
There is growing body of evidence to suggest that GBS is an antibody-mediated 
disorder in which complement fixing IgG1/3 subclass anti-ganglioside antibodies plays 
a major role in GBS pathogenesis. These antibodies are also directed against epitopes 
present on peripheral nerves and are induced through the mechanism of molecular 
mimicry with bacterial lipo-oliogosaccharides. (25) The specificity of these antibodies 
largely determines the clinical spectrum (pure motor, sensory-motor, Miller Fisher 
syndrome, etc). Current research into the pathogenesis of GBS is primarily focused on 
identifying humoral immunity and downstream effector pathways, including 
complement activation. Recent experimental evidence suggests that complement 
activation plays a crucial role in the development of neuromuscular weakness in GBS 
making compliment inhibitors and regulators attractive therapeutic targets. Indeed, 
when the effect of eculizumab- a humanised monoclonal complement inhibitor was 
studied in animal models of GBS, it showed that eculizumab prevented the formation of 
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membrane attack complex deposition on axonal surface and thus prevented 
antibody/compliment-mediated damage. (76) Encouraged by this finding Willison 
group has started a two-one randomised double blinded study of 30 patients comparing 
IVIG alone and IVIG with Eculizumab. This pilot study is essentially a safety and 
tolerability study but we will examine the efficacy of the treatment based on some 
secondary outcome measures. The study has been initiated in July 2014. 
 
1.7 GBS outcomes, outcome measures 
 
Although the outcome of most appropriately treated GBS cases are considered to be 
favourable, about 20 % patients remain significantly disabled at 12 months. (77) Most 
of the GBS outcome data comes from clinical trials and some prospective observational 
studies conducted in western world. Due to lack of systematic studies and infrastructure 
required for registration and monitoring of the GBS cases outcome data from 
developing countries are not available. In this section, we discuss GBS outcomes and 
their predictors. 
 
1.7.1 GBS Outcomes 
 
In context of GBS most widely studied outcomes are; a) Mortality (Death) b) 
Requirement of ventilation c) Disability; especially ability to walk independently at 3 
months, 6 months and 12 months d) Pain e) Fatigue. However, systemic long-term 
outcome data are not available. 
 
1.7.1.1 Mortality of GBS: 
 
GBS can be a life threatening disorder. Most common causes of death in GBS are 
respiratory failure, cardiovascular failure, pneumonia and autonomic disturbance. (39) 
Although, there were no large-scale prospective studies in Pre IVIG/PE era, some 
retrospective studies from western countries showed mortality rates of 2 to 5 % while 
around the same time, one study of 63 GBS patients from India showed mortality rate 
of 28 %. (78, 79) 
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Winer et al conducted the first well-designed prospective study in 1988. (39) In this 
study, authors recruited 100 patients with acute idiopathic neuropathy and followed 
them for 52 weeks. The study showed mortality of 13 %. The most common cause of 
death in this study was cardiac arrest. In post PE/IVIG era mortality data comes from 
various clinical trials performed after 1978. Meta analysis of five clinical trials 
comparing PE and placebo and a single trial of steroid comparing the placebo showed 
mortality of 5.9 % in the treatment group and around 5 % in the placebo group, 
suggesting that the availability of treatment like plasma exchange has not made 
asignificant difference in the mortality rates. (80) Similarly trials performed comparing 
two widely available treatments namely PE and IVIG continued to show mortality rates 
between 2.4 to 6.3 %.(81) Recently a Dutch group has published the data of 527 GBS 
patients recruited in one observational study and three therapeutic trials showing 
mortality of 3.9 %.(82) Out of fifteen patients who died during the follow up, 20 % died 
during the acute phase, 13 % died in plateau phase and 67 % of patients died during the 
recovery phase. Most common causes of death were respiratory and cardiovascular 
complications. 
 
1.7.1.2 Requirement of ventilation: 
 
Respiratory failure requiring mechanical ventilation (MV) is a serious complication of 
GBS. Respiratory failure in GBS is due to underlying inspiratory and expiratory muscle 
weakness. Often insidious in onset, it increases the risk of aspiration pneumonia and 
respiratory arrest. Various retrospective studies from pre PE/IVIG era showed that 
about 10- 33 % patients required MV. (39, 66) Data from various clinical trials 
comparing PE and placebo, IVIG and PE, continues to show the rates to be around 31 
%. (80) 
 
1.7.1.3 Disability: 
 
“Ability to walk independently” is the most common outcome measure has been 
studied in various clinical trials so far. In pre IVIG/PE era, one study showed that about 
20 % patients remained significantly disabled i.e. able to walk but unable to perform 
any manual work at 12 months also a proportion of patient remained bed bound or chair 
bound. (78) Other studies performed during that period also showed residual disability 
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rates between 7 to 22 %. (39)
 
 
 
 
Table 1-1 Outcome measures in various clinical trials 
Outcome 
Measure 
Number 
of 
Studies 
Studies 
Ability to 
walk at 6 
months  
1 GBS study Group 
1985 
Ability to 
walk at 12 
months 
2 Bernsen et al 2002 
Van Koningsveld 
et al 2004 
Full muscle 
strength at 
12 months  
5 Greenwood et al 
1984 
Osterman et al 
1984 
French Co-
operative study 
1987 
Farkilla 1987 
French C0-
operative study 
group 1997 
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In post PE/IVIG era, various controlled trials used different timings to measure the 
outcomes as outlined in the table below. 
 
Does ability to walk independently change with PE at 6 months? Only a single study 
performed comparing PEwith placebo has used this outcome measure. A study 
performed by GBS study group in 1985 showed that about 82 % of patients were able 
to walk independently at 6 months in PE group as compared to 71 % in control 
group,suggest very modest benefit. (83) 
 
Does ability to walk independently change with PE or IVIG at 12 months? A Study 
comparing IVIg with IVIGand PE combination showed 84 % of patients were able to 
walk independently at 12 months. (81) Considering the fact that about 82 % of patients 
were able to do so within 6 months, this benefit is not very substantial. Unfortunately 
there is no 12 months outcome data available for this outcome in patients without 
immunotherapy treatments and therefore no conclusion can be drawn about long-term 
efficacy of immunotherapy. 
 
Recovery of full motor strength at 12 months: French cooperative study group trial 
performed in 1987,comparing PE with no treatment, showed recovery of complete 
muscle strength in 52 % of untreated patient at 12 months, compared to 72 % in PE 
group. (72) However another study showed this rate to be 58 % only in treatment 
group, giving conflicting results. (84) 
 
Is immunotherapy with PE/IVIG useful? : Whilst above studies show only modest 
improvement in the long-term outcome, all the studies showed significant 
improvement in short-term disability measures. One such measure used in all trials is 
GBS disability (GBSD) score, also known as Hughes Disability score which scores 
disability from 0-6, where score of 0 is normal; 1 patient is capable of running with 
minor symptoms; 2 is walking independently; 3 is walking with assistance; 4 is 
bed/chair bound; 5 is ventilated and 6 is Dead. In all the trials GBSD score measured 
at the time of entry and 4 weeks after the starting of treatment, showed significant 
proportion of the patients improved by 1 grade in treatment group compared to 
untreated group. This clearly shows that immunotherapy hastens the recovery. 
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Table 1-2 Proportion of patients improved by 1 grade on GBSD with immunotherapy 
 
 
Plasma 
Exchange 
Group 
No 
Treat
ment 
 
(% of patients 
improved by 
>1 grade of 
GBSD 
(% of 
patients 
improve
d by >1 
grade of 
 at 4 weeks) 
GBSD 
at 4 
weeks) 
   
Greenwood et al, 
1984 50 % 40 % 
   
Osterman et al, 
1984 77 % 30 % 
   
The GBS Study 
Group, 1985 59 % 39 % 
   
French 
Cooperative 
Study 61 % 36 % 
Group, 1987   
   
French 
Cooperative 
Study 50 % 30 % 
Group, 1997   
   
Average 59.4 % 35 % 
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1.7.1.4 Relapse rates: 
 
 
Data from 5 trials showed that about 3.8 % of GBS patients have clinical relapses 
within 12 months of disease onset. 
 
1-3 Relapse rates in various clinical trials 
Study Relapse at 12 months 
  
Greenwood et al, 1984 1/14 
  
Osterman et al, 1984 1/18 
  
The GBS Study Group, 
1985 2/122 
  
French Cooperative 
Study Group, 1987 6/109 
  
French Cooperative 
Study Group, 1997 14/361 
  
Average 24/624 (3.8 %) 
   
 
 
 
 
 
 
1.7.1.5. Pain in GBS: 
 
Ruts et al performed a prospective study of 156 GBS patients and found that in about 
36 % of patients, pain was a presenting symptom irrespective of type of GBS. (85) 
Different types of pain reported by patients, which included radicular pain, meningism, 
painful paresthesia/dysthesia, and myalgia. With regard to long term outcome about 38 
% of patients complained of pain at 12 months. 
 
1. 7.1.6 Fatigue 
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Fatigue can be the most disabling symptoms in patients with immune mediated 
neuropathy and can occur even after apparent physical recovery, which may have 
profound impact on patients’ quality of life. In a study performed by Merkies et al on 
113 patients with immune mediated neuropathy, which included 80 GBS patients, 80 
% of patients reported fatigue as amongst three most disabling symptoms. (86) Only 
two studies have been performed looking at the long term fatigue data in GBS patients 
and both studies have shown that sever fatigue persists for long time in this group of 
patients even after apparent physical recovery. (87, 88) 
 
 
 
 
1.7.2 Outcome Measures: 
 
 
 
The major focus of modern day clinical practice is evidence based medicine. Evidence 
generated by sound research techniques has huge implications for not only clinical 
practice but also for health policies. In clinical research focus is largely on 
measurement of a particular outcome with or without a specific intervention. In 
context of GBS, “disability” is the most widely measured outcome. Unfortunately, 
there is no consensus-based definition of disability; however various conceptual 
models available which help guide the measurement. 
 
1.7.2.1 Defining Disability and Disability measurement in GBS: 
 
 
Various conceptual models available, these range from medical model of disability to 
social model, and some with intermix of both. As per world health organisation 
(WHO), disability is defined as an umbrella term for any impairment, activity 
limitation or participation restriction which limits functioning within personal and 
environmental factors. In context of GBS, disability has been traditionally defined by 
“ability to walk” and very little emphasis has been given on other medical or social 
parameters. 
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1.7.2.2 GBS Disability Scale: 
 
 
 
The very first attempt to develop a GBS disability scale was made by Hughes et al in 
1978. They designed a scale also called as ‘Hughes Disability scale’ or ‘Hughes 
functional scale’, in which they measured disability on a categorised scale of 0 to 6 
where 0: healthy; 1 minor symptoms but capable of running; 2: walking unaided but 
unable to run; 3: able to walk with a stick, appliance or support; 4 confined to bed or 
chair; 5 ventilated and 6: dead. (66) 
 
                  Table 1-4 GBS disability scale 
GBS disability score  
  
0 Healthy 
  
1 
Minor symptoms but able 
to run 
  
2 
Able to walk 
independently 
  
3 
Unable to walk 10 meters 
independently 
  
4 Bed bound or chair bound 
  
5 Ventilated 
  
6 Dead 
  
 
 
 
This scale has been widely used in clinical trials. While on the one side it has an 
advantage that each of the categories has been very well defined and is clinically 
relevant, which significantly increases intra rater agreement, a quality needed for a good 
multi centre study, the other side it has some disadvantages 1) GBSD is lower limb 
specific, which means it does not capture any upper limb disability 2) It is less sensitive 
in capturing small clinical change in early stages of GBS. This was first demonstrated 
by Ropper et al in 1988 in a series of 96 GBS patients treated with PE and out of those 
96 patients 10 patients had early relapse following the first PE, evident by decrease in 
muscle strength and vital capacity. (89) These patients were subsequently treated with 
additional course of PE and showed significant improvement. One of the interesting 
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points noted by Ropper et al was that some of these patients with obvious clinical 
deterioration noted on muscle strength did not have any change in their GBSD scale, 
highlighting the fact that GBSD scale was relatively insensitive in identifying a small 
clinical change especially in acute settings. A similar observation was by Kleyweg et al. 
(90) In their study authors introduced a new score; MRC sum score which is a 
summation of the strength of 6 muscle groups on each side and the score ranges from 0 
to 60 where 0 represents complete paralysis and 60 represents full muscle strength. 
They compared MRC sum score with GBSD scale in patients participated in Dutch 
GBS trial and measured the sensitivity of GBSD and MRC sum score by simultaneously 
measuring these two scores at various disease stages and showed that when patient with 
clinical deterioration has simultaneous decline in their MRC sum scores but not in 
GBSD scale. One of the major issues with the ordinal measurement scales is that their 
nonlinearity and GBSD being inherently an ordinal scale, the distance between different 
categories is not the same. For example on a measurement scale can the distance 
between dead (GBSD 6) and being ventilated (GBSD 5) be the same as the distance 
between being healthy (GBSD 0) and able to run (GBSD 1) ? And the answer is 
probably not and therefore using these values for parametric calculations defies the 
principles of measurement science. 
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                1.7.2.3 Overall Neurological Disability Scale (ODSS) 
 
 
 
In 1999, based on Guy’s neurological disability scale, Sharrack et al developed 
Overall Neurological DisabilitySum Score (ODSS), which included both upper limb 
and lower limb disability with a total score ranging from 0(no disability) to 12 (Severe 
disability). (91) In this scale various upper limb functions were graded as being “not 
affected”, “affected but not prevented” and “prevented”, these results were then 
translated into numbers ranging from 0 to 5, for upper limb disability. Similarly lower 
limb functions were graded depending on ability to walk but not run, these results then 
translated into lower limb scores of 0 to 7. 
 
In order to be clinically useful, any measurement scale must be able to satisfy all 
clinimetric properties such as validity, reliability and responsiveness. Validity here is 
defined by the relation between the disability and the scale used to assess the 
disability, which usually relies on expert judgements, by establishing high correlation 
between the scale and a gold standard. Reliability assesses the internal consistency in a 
multi item scale with good intra and inter observer agreement also called K value. 
Responsiveness of the scale is defined by scale’s ability to detect any minor clinically 
meaningful change when evaluating the benefits of a particular medical intervention. 
 
In a study involving 113 immune mediated polyneuropathy Merkies et al, showed that 
ODSS was very simple to use, met all the clinimetric requirement and compared to 
Hughes disability score it was shown to have captured wide range of disability and 
therefore was better at monitoring the clinical progress of the patient. (92) In 2006, the 
same authors compared five different disability scales with short form health survey 
(SF-36) in patients with immune neuropathies and showed that, compared to other 
scales ODSS was better at relating to patient’s own perception of disability. (93) 
However this scale also had some limitations such as “ability to run” was not included 
in the scale and again being an ordinal scale it deemed not suitable for parametric 
calculations. (94) 
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Figure 1-3 Overall Neurological Disability Sum Score 
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1.7.2.4 Overall Neuropathy Limitations Scale (ONLS) 
 
Considering the shortcomings of ODSS, especially scale’s inability to assess functions 
like running and climbing stairs, and to reduce the ceiling effect, Graham et al 
developed another scale called Overall Neuropathy Limitations Scale (ONLS) (95). 
ONLS was assessed for inter rater reliability and content validity and responsiveness. 
Analysis showed that ONLS had better content validity and in terms of construct 
validity. ONLS correlated very closely with ODSS and other measures of impairment 
such as MRC sum scores, limitation, handicap and health related quality of life scores. 
ONLS also showed very good inter rater agreement and similar responsiveness to 
ODSS with retaining its simplicity. 
 
 
 
 
 
 
 
 
 
51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 : Overall Neuropathy Limitation Score (ONLS 2006) 
 
 
 
 
 
 
 
1-4 Overall neuropathy Limitation Score  
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1.7.2.5. Development of New outcome measures: 
 
 
 
As described earlier, most outcome measures used in GBS are ordinal, multi-item, 
composite scores and have been designed using “classic test theory”. Data collected 
using such measures are qualitative and traditionally the numbers have been assigned 
to each descriptive category and based on these numbers, parametric calculations are 
being performed, assuming the linearity of the scales. Interestingly, most clinical trials 
have been conducted using these ordinal scales, which hampers the interpretations and 
results of clinical trials. To mitigate the shortcomings of currently available scales new 
outcome measures, which are based on modern clinimetric measurement techniques 
have been proposed. In the new technique measurements are performed at interval and 
ratio level, which in turn increases the precision. Not only that, the distance between 
two response categories is known and therefore parametric calculations can be easily 
performed. One such modern techniques is called “Rasch model” has generated huge 
interest. This probabilistic model has been designed using “Item Response Theory” 
and is based on logical assumption that a patients with high ability is more likely to 
give affirmative response to a particular “Task” or “Item” compared to a patient with 
less ability. (96) The probability of a patients to give affirmative response is also 
depends on “Task” or “Item” difficulty. Thus patient’s ability and “Task” or “Item” 
difficulty having logarithmic relations are measured using a logit scale and thus 
ordinal data can be converted into an interval scale. (97) 
 
 
 
1.7.2.5.1 Rasch Based Overall disability scale: 
 
 
A generic, Rasch based measure, ACTIVLIM has been designed to capture and 
monitor disability in neuromuscular disorders in children and adults. (98) However 
item weights obtained from this scale were significantly varied from those obtained 
from inflammatory neuropathies such as GBS, CIDP and multifocal motor 
neuropathies, highlighting the need of disease specific Rasch based outcome measure. 
In one such attempt to develop a disease specific outcome measure, van Nes et al 
constructed a preliminary scale with 146 items obtained from WHO international 
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classification of functioning, disability and health and patient questionnaire. 
 
This preliminary scale was further assessed in 294 patients using various Rasch 
parameters and finally a 24-item Rasch based overall disability scale was constructed. 
(100) 
 
 
 
R-ODS was further compared to ODSS and as outlined in the figure, it was shown to have 
good representation of wider range of item difficulties and therefore was better at targeting 
patients with different disability levels. R-ODS was also shown to have good reliability 
and validity. Thus, development of this linearly weighted scale was a remarkable step 
forward in terms of outcome measures in peripheral neuropathies (PN), one of the limiting 
factors is its disease specificity. When R-ODS was analysed in Multifocal Motor 
Neuropathy (MMN) subgroup, it strongly differed to other PN, in terms of item 
difficulties. This was due to selective and asymmetric, especially distal involvement of 
different muscle groups in MMN and items such ‘turn a key” and “making a 
sandwich” were considered more difficult in this subgroup compared to other PN. The 
other limiting factor was applicability of this scale to different geographically and 
culturally diverse populations as this scale was designed using a patient cohort from a 
single country. Thus further studies are needed to assess its responsiveness and cross 
cultural applicability. 
 
 
 
1.9 Conclusions: 
 
GBS is a spectrum of post infectious inflammatory polyneuropathy with various 
clinical, electrophysiological and regional variants. It remains a clinical diagnosis. 
While we have made considerable progress in our understanding of underlying 
immunopathogenesis, this has not yet translated into better diagnostic and therapeutic 
avenues. Clearly, the discovery new antigenic targets and new EP variants has 
generated significant interest in this area of research, however their precise role as 
diagnostic tools is yet to be established. Understanding various immunological factors 
and their association with different clinical and EP variants is of paramount 
importance and holds the key for development of new therapeutic targets. 
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Similarly, due to heterogeneous nature of the disease identification of underlying 
predictive factors also holds key for development of good prognostic models so that 
individual patients with poor prognosis can be identified early and can be targeted with 
novel treatment. New monoclonal antibodies against compliment activation have 
raised hopes for availability of better therapeutics targets. 
 
In order to study these issues in greater detail, systematic, well organised, international 
observational studies are needed 
 
 
 
1.10 Aims 
 
 
 
As outlined earlier in this chapter, GBS remains a clinical diagnosis with highly 
diverse clinical course and outcome. Currently available literature suggests that about 
20 % of patient remained severely disabled at 1 year and about 5 % of patient die. 
Current research in GBS focuses on two major issues: 1) identification of early 
prognostic markers of poor outcomes 2) identification of early diagnostic biomarkers 
of the disease.  
Early identification of patients with poor prognosis is very important, and if identified 
early, this group of patients may benefit from additional treatment when it is likely to 
be most effective. This can be achieved by developing good prognostic models and 
biomarkers based on clinical, serological and genetic information on patients. At 
present there are no readily applicable and validated prognostic models available to 
identify this group of patients with poor prognosis. (133) Previous studies have 
identified age, type of preceding infection, extent of nerve damage; immune factors 
including anti glycolipid antibodies and genetic polymorphisms as important 
prognostic markers and based on this information various prognostic models have been 
designed. However these studies have been performed on a small number of relatively 
homogenous patient population and therefore the results of these studies need to be 
validated by a systemic large multi centre study. 
 
Identification of anti glycolipid antibodies in a proportion of GBS patients has 
generated considerable interest in the field of biomarker development; however their 
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diagnostic role has been constantly debated. Moreover recent discovery of anti 
ganglioside complex antibodies has added further complexity to this field and 
therefore a systematic, well designed, clinico-serological association study is required 
to investigate their diagnostic role in GBS. 
 
As GBS is relatively a rare disorder, we conducted an international, prospective, 
observational study called ‘IGOS’ to address above issues. It aimed to study at least 
1000 patients worldwide over 3 years. The study provides an excellent opportunity to 
study various clinical and biological factors in a systematic way with an aim to 
validate existing prognostic models of GBS and also to develop new prognostic 
models. IGOS has generated a large clinical and serological database, which will 
enable screening of these sera for new diagnostic biomarkers of the disease. 
 
Thus, the overall aims of this study (IGOS) were: 
 
 To identify clinical and biological determinants and predictors of disease course 
and outcome in individual patients with GBS, as early as possible after onset of 
disease 
 
 To identify new serological diagnostic markers 
 
 To validate already existing prognostic models and develop new prognostic 
models 
 
 
Due to various limitations in access of the international data, we first sought to analyse 
IGOS UK database of 122 patients with following aims:  
 To perform a pilot analysis IGOS UK cohort of GBS patients with an opportunity 
to identify questions of interest for the main study and to learn lessons from this 
 To describe the clinical features and current treatment trends in the UK 
 To study the short term as well as long term outcomes including mortality, 
disability and QoL 
 To externally validate the existing prognostic models- EGOS and MEGOS 
 To compare newly developed rajabally’s EP criteria with existing criteria and to 
determine whether single study performed using Rajabally criteria is sufficient to 
establish final EP diagnosis
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Chapter 2 Materials and 
methods
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2.1 Introduction: 
 
 
 
 
This chapter provides a detailed description of the general methods used in the 
International GBS outcome study. Methodology, protocol and endpoints relevant to 
this study have been discussed. While recruitment into IGOS study continues at the 
time of writing this thesis, I analysed clinical data collected between May 2012 and 
January 2015 at 15 different UK centres. 
 
Govind Chavada and Hugh J Willison were the country co-ordinators for IGOS UK. 
Individual principal investigator at different UK centres collected patient’s 
recruitment, clinical and serological data. Clinical data was transferred on to IGOS 
website (www.gbsstudies.org). All the serological samples were stored at University of 
Glasgow. 
 
 
 
2.2 International GBS Outcome Study (IGOS) 
 
 
 
 
 
2.2.1 Study design 
 
 
 
IGOS was a prospective observational international multi-centre study. It aimed to 
recruit at least 1000 patients with GBS or variants of GBS, including the Miller Fisher 
syndrome (MFS) and overlap syndromes with a follow-up period of one year with an 
option to extend this period to two and three years. As part of the study a detailed and 
standardised database on clinical features, treatment, and diagnostic electrophysiology, 
serum samples and DNA samples were obtained at specific visits. There were two 
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optional modules of the study (1) to collect cerebrospinal fluid (CSF) during routine 
diagnostic work-up for proteomic studies, and (2) to conduct an extended follow-up of 
two and three years (Figure 2.1). 
 
 
 
 
 
 
 
Figure 2-1 International GBS Outcome Study (IGOS) database and bio bank.  
The striped blocks refer to optional sub studies. Clinical data will be obtained using standard 
forms regarding personal data (P-form), clinical characteristics at study entry (A-form), at 1 
and 2 weeks (B-form), and at later visits (C-form). At the same visits data are collected about 
treatment interventions and intensive care (T-form). Blood samples are obtained as indicated 
for serial serological studies and for DNA extraction (single sample in the first month). Routine 
diagnostic electrophysiology will be conducted in the first week, and is possible at 4 weeks. 
*Admitted patients at 8 weeks and 13 weeks will have a full examination and serum sampling; 
discharged patients at these visits a telephone assessment only and no serum sampling. 
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The clinical, treatment and electrophysiology data and the biomaterial obtained in the 
first two weeks of inclusion were used to predict the clinical course and outcome in 
individual patients at four weeks and at later time points during follow-up. 
 
The first two weeks after entry reflected the time window in which additional therapy 
was likely to be most effective. Questionnaires for the first three visits have focused on 
potential prognostic factors, including the clinical features used in previously designed 
prognostic models such as the EGOS and MEGOS. Questionnaires for later visits has 
focused on clinically relevant endpoints, including: extent of weakness, autonomic 
dysfunction, respiratory insufficiency, treatment-related fluctuations, recurrences, 
complications, disability, pain, fatigue, and transition to chronic inflammatory 
demyelinating polyneuropathy (CIDP). 
 
 Serum samples were collected and will be tested for infection serology and for the 
presence of antibodies to gangliosides, which may be related to the clinical course and 
outcome. In addition, sera will be tested for the presence of antibodies to the 
combination of different gangliosides (ganglioside complexes), which frequently occur 
in GBS. Antibodies to other peripheral nerve will also be determined. 
 
In patients treated with intravenous immunoglobulin (IVIg), the serum samples will be 
used to define the variation in pharmacokinetics in relation to outcome. The serum 
samples will also be used to determine other potential biomarkers for inflammation 
and peripheral axonal and myelin damage. 
 
DNA extracted from a single blood sample obtained in the first month will be used to 
determine the relation between gene polymorphisms and disease susceptibility, clinical 
course and outcome. 
 
In addition to this obligatory core study of the IGOS, there was an option to participate 
in two additional sub studies. It was anticipated that these studies would be performed 
only in a proportion of the patients and centres. These optional additional studies were: 
 
(1) Cerebrospinal fluid (CSF) biomarkers. 
 
Most patients will undergo a spinal tap as a routine procedure in the diagnostic work-
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up of GBS. The observed number of cells and concentration of protein in CSF was 
registered in the core study. In additional there was an option to collect an extra 
sample of CSF to determine biomarkers for nerve damage, which are related to 
outcome. These biomarkers will be examined by advanced proteomics, which require a 
special procedure for conservation and storage of this extra CSF sample. 
 
(2) Long-term outcome 
 
Most recovery occur in the first year after onset of disease, but further recovery has 
been reported in a proportion of patients. To define the long-term outcome of GBS and 
to be able to predict this outcome, there was an option to conduct an extended follow-
up in which patients are re-assessed at two years and three years after onset of disease. 
 
2.2.2 Patient Inclusion criteria 
 
 
 
 Fulfil the diagnostic criteria for GBS of the National Institute of Neurological 
Disorders and Stroke (NINDS) (as outlined below) 
 
 In addition all patients with Miller Fisher syndrome (MFS) and other variants 
of GBS, including overlap syndromes can be included, for which additional 
diagnostic criteria will be provided. (as outlined below) 
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 Inclusion of all males and females patients over the age of 18 years, 
independent of disease severity and treatment Inclusion within two weeks of 
onset of weakness (or other symptoms attributed to GBS) 
 
 Opportunity to conduct a follow-up of at least one year 
 
 
 
 
 
 
 
2.2.3 Diagnostic criteria for Guillain-Barré syndrome (GBS) 
 
 
Features required for diagnosis 
 
 Progressive weakness in both arms and legs (might start with weakness only in 
the legs) 
 
 Areflexia (or decreased tendon reflexes) 
 
Features that strongly support diagnosis 
 
 Progression of symptoms over days to 4 weeks 
 
 Relative symmetry of symptoms 
 
 Mild sensory symptoms or signs 
 
 Cranial nerve involvement, especially bilateral weakness of facial muscles 
 
 Autonomic dysfunction 
 
 Pain (often present) 
 
 High concentration of protein in CSF 
 
 Typical electrodiagnostic features 
 
Features that should raise doubt about the diagnosis 
 
 Severe pulmonary dysfunction with limited limb weakness at onset 
 
 Severe sensory signs with limited weakness at onset 
 
 Bladder or bowel dysfunction at onset 
 
 Fever at onset 
 
 Sharp sensory level 
 
 Slow  progression  with  limited  weakness  without  respiratory  involvement  
(consider  subacute  inflammatory 
 
 demyelinating polyneuropathy or CIDP) 
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 Marked persistent asymmetry of weakness 
 
 Persistent bladder or bowel dysfunction 
 
 Increased number of mononuclear cells in CSF (>50×10E6/L) 
 Polymorphonuclear cells in CSF 
 
 
 
 
2.2.4 Diagnostic criteria for Miller Fisher Syndrome (MFS) 
 
Features required for diagnosis 
 
 Bilateral ophthalmoparesis or ophthalmoplegia 
 
 Ataxia 
 
 Areflexia (or decreased tendon reflexes) 
 
 Features that support diagnosis 
 
 Progression of symptoms over days to 4 weeks 
 
 Relative symmetry of symptoms 
 
 Mild limb weakness (in case of prominent limb weakness, consider GBS-MFS 
overlap syndrome) 
 
 Mild sensory symptoms or signs (in case of prominent sensory symptoms or 
signs, consider GBS-MFS overlap syndrome) 
 
 Facial palsy and/or bulbar palsy 
 
 Presence of serum IgG antibodies against ganglioside GQ1b Nerve conduction 
studies: no changes in extremities 
 
 High concentration of protein in CSF, cytoalbuminologic dissociation 
 
Features that should raise doubt about the diagnosis 
 
 Alterations in consciousness 
 
 Corticospinal tract signs 
 
 Fever at onset 
 
 Marked persistent asymmetry of weakness 
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2.2.5 Criteria for inclusion of patients in the optional research modules of 
the IGOS: 
 
 
 
Additional informed consent was required for each optional research module: 
 
 
 CSF biomarkers: additional volume obtained at diagnostic spinal tap 
 
 Long-term outcome: additional clinical assessments at two and three years 
 
 
 
To limit selection bias as much as possible there are no exclusion criteria to be 
included in IGOS. 
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2.2.6 Clinical Assessments 
 
 
Clinical assessments were performed according to a standard protocol at eight visits 
using specific data entry forms for each visit (Figure 2). Forms A and B focused on the 
clinical predictors of outcome; Form C focused on outcome measures which included 
the GBS disability Score, MRC sum score, Rasch-built MRC score, Overall 
Neuropathy Limitations Scale (ONLS), Rasch-built Overall Disability Scale (R-ODS), 
Fatigue Severity Scale (FSS) (and Rasch-built FSS), and the EuroQol EQ-5D health 
questionnaire. In addition information regarding involvement of cranial, sensory and 
autonomic nerves, pain and complications were collected. If a patient has been 
recruited at a time point (within 14 days of onset) when they were already recovering, 
additional information about the historical peak disability and the date it was reached 
was collected. 
 
All patients had a full neurological examination at entry, and at 1 week, 2 weeks, 4 
weeks, 26 (± 2) weeks and 52 (± 2) weeks after entry. Patients who were still admitted 
to the hospital at 8 (±1) weeks and 13 (± 1) weeks were examined additionally at those 
time points, but once discharged, patients at these visits were not been seen and had a 
telephone assessment of the GBS disability score, ONLS, R-ODS, FSS and EuroQoL 
EQ-5D only. 
 
2.2.7 Collection of treatment data and admission to intensive care unit data 
 
 
Information concerning treatment and complications of treatment, admission to ICU, 
intubation and artificial ventilation was updated at all visits during follow-up (Figure 
2). This information was collected via Form T . These data will be used to define the 
current practice of treatment of GBS in various centres and countries and the side 
effects of treatment. Some patients with poor prognosis received a second dose of IVIg 
as a routine practise. Therefore, information collected from form T will be used to 
compare the functional outcome between the patients who would have received a 
single dose of IVIg and those who would have received a second dose of IVIg. (I-SID 
GBS study). This will be one of many specific research areas. Some patients would 
have not received any treatment and would have not required ventilation or admission 
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to an ICU, these patients were still recruited into the study, and in these patients this 
questionnaire remained empty. 
 
2.2.8 Routine diagnostic electrophysiology 
 
 
Most patients with GBS have routine diagnostic electrophysiology examinations to 
confirm the diagnosis and to specify the electrophysiological subtype of GBS. 
Although a specific EPS protocol was designed and recommended, due to pragmatic 
nature of this study, the raw data of the electrophysiological examination was 
collected. Diagnostic guidelines of GBS recommend conducting a diagnostic 
electrophysiology study in the first week of hospital admission on at least four 
peripheral nerves in arms and legs. Many clinics routinely perform a second diagnostic 
electrophysiology at four weeks, since the electrophysiological subtype of GBS 
frequently changes in the acute phase of disease. In these cases the raw data from 
routine EPS was also collected. 
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2.2.9 Collection of blood samples to obtain serum and DNA 
 
 
Blood samples were obtained at all visits when the patients had a full clinical 
assessment, which is at entry (before start of treatment when possible), and at 1 week, 
2 weeks, 4 weeks, 23 weeks, and 52 weeks after entry (Figure 2). Additional samples 
were collected at 8 weeks and 13 weeks in patients still admitted to the hospital. No 
serum samples were obtained from patients who were discharged at the 8 weeks and 
13 weeks time points, since these patients had telephone assessments only. Blood 
samples were drawn to obtain serum (24 ml at entry and 16 ml at later visits) and 
DNA (4 ml at any visit in the first month). All the blood samples were obtained using a 
standard operating procedure. The first serum sample was obtained before the start of 
treatment. Later serum samples were collected anytime during the treatment. All the 
blood samples were sent to the Coordinating Centre of the country or region. 
 
2.2.10 Collection of CSF for biomarker studies 
 
 
Most patients have a spinal tap to examine CSF for routine diagnostic work-up of 
GBS. In case of a diagnostic puncture there was an option to collect an additional 
volume of 2 ml of CSF for biomarker studies. If the patient did not have a diagnostic 
puncture, or if the puncture was performed before inclusion in the IGOS, no additional 
spinal tap was performed only to be able to participate in this research module. Special 
handling of the CSF samples required for advanced proteomic studies. A standard 
operating procedure for the CSF sampling, transport and storage was provided. In 
short, CSF samples were centrifuged within one hour after the spinal tap. The 
supernatant (without pellet) is removed and immediately stored in a polystyrene tube 
at -20 
0
C until it is transferred to the coordinating centre of the country. Additional 
informed consent is required to participate in this optional research module. 
 
2.2.11 Extended follow-up of two and three years 
 
 
To determine the long-term residual deficits, the patients had a telephone assessment at 
two additional visits: at 2 years (104 ± 4 weeks) and at 3 years (156 ± 4 weeks) after 
onset of disease. The clinical assessments at 2 and 3 years were performed using Form 
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C and clinical outcome measures as in the assessments at the visits at 4 weeks to 1 year 
(see Figure 3 and Website questionnaires). This questionnaire contains the following 
clinical assessments scores: GBS disability score, ONLS, R-ODS, FSS, and EuroQoL 
EQ-5D. There was also an option to neurologically examine the severely patients at 
these visits to evaluate the residual cranial nerve and sensory involvement, pain, 
autonomic dysfunction and complications. Additional informed consent is required to 
participate in this research module. 
 
2.2.12 Definition of first day and follow-up time points 
 
 
IGOS data were compared with data derived from previous trials. Therefore, the first 
day of the IGOS was defined as the day of the start of this treatment. The patients had 
a full examination on the same day and this data was registered on the website. 
 
Patients with mild GBS, who did not receive any treatment, in which cases the first 
day of the IGOS was defined as the day of their registration into the study. 
 
Patients who already had received the treatment, for instance in another hospital from 
which the patient was transferred, the first day of the IGOS was defined as the day of 
their registration into the study. 
 
 
 
 
2.3. Development of IGOS website 
 
 
IGOS was a multicentre registry database and therefore for ease of administration a 
web based data entry system was developed with help from professional web 
designers. The website was designed to inform patients and researchers and to assist 
and control data entry. This web based data entry system met the highest standards for 
security and privacy. The IGOS database and bio bank was strictly anonymous: all 
registered patients were assigned a unique number. Privacy-sensitive personal data 
including name, address and date of birth of the patients were obtained by a distinct 
Form P and this information was available only to the local participants and the 
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country co-ordinators, and was stored separately from the data for research. The 
website was constructed in a highly secured environment that can be entered by 
licensed researchers only. Continuous backup of central database was undertaken and 
the data was continuously monitored for any inconsistencies. The website also 
provided the time-stamped electronic audit trails to identify what, when and by whom 
changes were made in the records. Patients were first checked for inclusion criteria. 
Eligible patients received a unique identification code, which was used throughout the 
study to ensure the anonymity. Patient information forms and informed consent forms 
in native languages were available at the website. The coordination centres provided 
the most common translations, but other translations (and back translations) were 
developed in collaboration with the participants. Data entry at the eight visits were 
standardized by using predefined questionnaires for each visit provided by the website. 
The website also provided explanations for several items and, if needed, the participant 
could ask for further help by e-mail to the Coordination centre. The website performed 
instant and automatic quality control of the data during input. At entry a schedule was 
provided with the dates for the next standard visits. The form of visit 1 (entry) needed 
to be completed on the same day, otherwise it was considered to be a missed visit. For 
visit 3, and 4 (on week 1, week 2 and week 4) a maximum of 1 week of window 
available to fill in the form, otherwise it was considered to be a missed visit. For visit 5 
and 6 (on week 8 and week 13) there was a maximum of 2 weeks to fill in the form 
and for visit 7 en 8 (on week 26 and week 52 there is a maximum of 4 weeks. 
Reminders for data entry were sent to the researcher automatically by e-mail before the 
next visit. Instant updates of the patients included were provided. 
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Figure 2-2 IGOS Structure 
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2.4 Organisation 
 
 
The members of Inflammatory Neuropathy Consortium conducted IGOS. A steering 
committee was formed, who supervised the development of study protocol and 
subsequently monitored the progress of the study. the committee was chaired by Dr 
Bart Jacobs. To develop sound prognostic models with sufficient statistical power a 
study with large number of patients was required. Due to low incidence of the GBS, 
international collaboration required. Members of Peripheral nerve society were 
informed and country coordinators were identified for each country. Each country 
coordinator, in turn was responsible for development, monitoring and support of local 
country network. The main co-ordinating centre was located in Rotterdam, who 
supported the country coordinators when required. 88 centres from 14 countries had 
participated in the study. By end of April 2016, 1265 GBS patients were recruited into 
the study. 
 
2.4.1 IGOS UK 
 
 
In the UK, three country Coordinators were identified (Prof Hugh Willison, Dr Mike 
Lunn, Dr John Winer). Dr Govind Chavada was appointed as clinical research fellow. 
Ethics application (11/WS/0118) to local and national Research and Ethic Committee 
(REC) was submitted to West of Scotland REC (4). Once ethical approval was 
obtained nationwide research and development approvals were sought for NHS 
England, NHS Scotland, NHS Wales and NHS Northern Ireland through a separate 
procedure. Individual applications were made to 4 national bodies. Once R&D 
approvals were in place, local principal investigators were identified. 
 
Fifteen centres across the Scotland and England participated in the study. Between 1st 
May 2011 and 14 April 2016, 154 GBS patients were recruited into the study. For the 
purpose of analysis, only 122 patients recruited between May 2012 and January 2015 
were considered as these patients had completed 12 months follow up visits at the time 
of analysis (January 2016). Out of 122 patients 8 patients were excluded from final 
analysis due to protocol violation and incorrect diagnosis. Forty one patients were 
recruited form Glasgow, 3 patients from Pinderfield, 2 from Leeds, 6 from Bradford, 5 
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from St Georges hospital London, 2 from National Hospital of Neurology, Queen 
Square, London, 8 from Kings College University Hospital of London, 9 from 
Cambridge, 4 from Sheffield, 1 from Ipswich, 9 from Newcastle, 1 from Birmingham, 
13 from Oxford, 8 from Liverpool, and 2 from Middleborough. At all centres, patients 
diagnosed with GBS were notified to local research team by clinical care team 
(treating neurologist/direct care team), who in turn formally assessed all patients for 
the suitability of the study. Only treating neurologists had access to patient records 
without explicit consent in order to identify potential participants, and to check 
whether they met the inclusion criteria or to make the initial approach to patients. A 
member of the local research team took consents. Before obtaining consent 
participants were given both verbal and written information about the study. 
 
Transportation and storage of bio samples constitute an important aspect of the IGOS. 
In the UK, we have designed a very easy and reliable transportation system in which 
co-ordination centre in Glasgow provided a welcome pack to each participating centre 
which contains pre-labelled bio sampling kit, with almost 100 % recollection rate. 
Similar approach was acquired at other coordinating centres. 
 
 
Since the study was ongoing at the time of my data analysis was limited to UK patients 
only. The website was managed by the main co-ordination centre in the Netherlands 
and release of the data required permission from steering committee and a complete 
data quality check, since neither of these been done at the time of analysis, I was 
unable to assess the complete data set. However, as a country co-ordinator, I was able 
to assess the UK data and therefore all the relevant data was manually transcribed from 
the IGOS website to an excel sheet for the analysis. Moreover the data quality check 
had not been performed at the time of this analysis.
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2.4.2 Collection of controls sera 
 
 
GBS is a post infectious inflammatory disorder. IGOS aimed to develop new 
biomarkers of the disease and to validate these biomarkers; we needed to compare 
them with samples (at least 1000) from healthy volunteers (pre-post vaccination) (300) 
and patients with recent infection (300) and other neurological diseases (300). 
Therefore, blood samples were collected from healthy volunteers (pre and post 
vaccination), patients with recent infection and other neurological disorders after 
appropriate consenting procedure. 
 
 
 
 
Inclusion criteria for controls include: 1) Healthy volunteers (pre and post vaccination) 
2) patients with recent infection 3) patients with other neurological disorders other 
than GBS 4) any adult above age of 18 and ability to give informed consent. 
 
Most control samples were collected at Glasgow site. Patients attending neurology 
outpatients were approached for OND controls. For pre-post vaccination healthy 
controls, participants (NHSGGC staff) attending annual flu vaccination clinics were 
approached and pre vaccination and 2 weeks post vaccination samples were collected. 
Post infectious controls were identified from infectious disease units. 
 
2.5 Statistical analysis 
 
Statistical methods used for the analysis of IGOS UK data have been described in 
detail in individual chapter. In general the statistical analysis presented in this thesis 
was performed mainly with IBM SPSS statistics (SPSS Chicago, Illinois, USA v.21) 
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3.1 Introduction: 
 
This chapter describes basic demographics, clinical features and treatment patterns of 
UK GBS patients.  I first probed the IGOS UK database to determine the baseline 
demographic including age, sex, preceding infections, presenting symptoms and signs, 
speed of onset and recovery. We also looked at the CSF characteristic and frequency 
of pain in acute phase of the disease. All together 122 patients from 15 UK centres 
were recruited between May 2012 and January 2015. Out of 122 patients only one 
patient had incorrect diagnosis. This patient was initially diagnosed to have MFS, 
however subsequently diagnosis was changed to brainstem demyelination. Seven 
patients with GBS were excluded from analysis due to protocol violations. All these 
patients were included beyond two weeks of onset of symptoms namely weakness. 
Altogether data from 114 GBS patients was analysed. 
 
 
 
3.2 Age, Sex, Preceding infections & other clinical features: 
 
Fifty six % patients were male and 44 % of the patients were female. Age distribution 
of all patients ranged from 18 to 83 years. Age demographic chart showed patients 
from all age groups being affected but more so in the fifth, sixth and seventh decade. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1 Age distribution of IGOS UK cohort 
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Seventy eight % of patients had preceding infections. One patient had GBS following 
stem cell transplant. Twenty two % of patients did not have any infectious trigger. 
Amongst the patients with preceding infections, 33 % had diarrhoea, 33 % had upper 
respiratory tract infections, and other infections group had common cold (3.5 %) and 
flu like illness (1.8 %). About 2.6 % patient had GBS following vaccination. 
 
                 Figure 3-2 Frequency of antecedent Infection 
 
Mean duration between infection and onset of symptoms was 15 days and median 
duration was 10 days with a range of 0-62 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antecedent Infections 
Cholangitis 
Common cold  
Diahorrea 
Flu 
No 
Rubella  
Sinusitis 
Stem Cell Transplant 
Figure 3-3 Median duration between preceding infection and 
onset of weakness 
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About 58 % of patient had pain at the time of onset of symptoms and about 54 % of 
GBS patients had cranial nerve involvement. CSF analysis was performed in 93 
patients (81.57 %). Mean duration of OOW and CSF study was 4.9 days (range 0-13 
days). Mean CSF white cell count was 2.8/cumm (range 0-18). Mean CSF protein was 
1.07 gm/L (Median 0.67 gm/L, Range 0-11.65 gm/L). There was statistical difference 
in CSF protein values in patients CSF study performed within 7 days of OOW and 
after 7 days of OOW (Mean 0.93 gm/l within 7 days Vs Mean 1.54 gm/l after 7 days P 
0.03).  Out of 22 patients, who did not have CSF studies performed, only one 
investigator had a set pattern of not performing CSF in any patient recruited in that 
centre. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4 Proportion of patients with pain 
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3.3 Frequency of clinical Variants: 
 
Symmetrical ascending weakness with very minimal sensory symptoms and signs is a 
typical feature of GBS. For clinical classification, we considered this type of GBS- a 
sensory motor GBS. To determine the frequency of different clinical variants we first 
probed the database and looking at the entry visit and subsequently compared it with 
other visits to check for consistent recording of clinical variants. Sixty six % of 
patients had typical sensory motor GBS, 16 % had pure motor GBS, 6.1 % had MFS- 
GBS overlap syndrome, 4.3 % had pure MFS, 2.6 % pure sensory and only 1 % had 
ataxic variant. About 2.6 % of patients had acute onset CIDP. Of interest, two patients 
who were clinically classified as “Pure motor GBS” had sensory symptoms and also 
sensory deficit on examination at the entry point. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean age for sensory-motor GBS patients was 56.2 years and mean age for pure motor 
variant was 54 years. There was no statistical difference in age of both groups (P 0.72). 
However there was significant association identified between preceding infection and 
type of GBS. All pure motor GBS patients (100 %) had preceding infection as opposed 
to 70 % patients with sensory motor GBS had preceding infections (P 0.005). Patients 
with Pure Motor GBS had either diarrhoea or upper respiratory tract infection while 
patients with sensory motor GBS had other infections such as common cold, flu and 
cholangitis. None of the patients with A-CIDP had preceding infection. 
Figure 3-5 Frequency of clinical Variants 
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All five patients of MFS had preceding infections (3 URTI, 1 Diarrhoea, 1 Rubella). 
Similarly all patients with MFS-GBS variant had either diarrhoea or URTI as 
preceding infections. Two out of 3 sensory GBS patients had preceding infections. 
Mean CSF protein value of sensory Motor GBS was 1.25 gm./l whereas mean CSF 
protein for Pure motor GBS was 0.63 gm./l. There was no statistical difference 
between the two values (P 0.179). However, overall CSF protein was elevated in both 
variants. Similarly CSF protein was elevated in MFS and MFS-GBS variants as well 
(Mean 0.90 gm./l) 
 
 
 
3.4 Speed of onset, Progression and recovery patterns in 
acute phase: 
 
 
Out of 114 patients; 18.4 % had mild GBS, defined by GBSD < 3 at nadir and 81.57 % 
patients had severe GBS defined by GBSD > 2 at nadir. Mean duration of onset of 
symptoms (OOS) and hospital admission (HA) was 3 days (Range 0-11 days). There 
was weakly negative correlation between duration between onset of symptoms (OOS) 
and date of hospital admission (HA) and GBS disability scores (R -0.39 CI -0.21 to -
0.54). Similarly there was weakly positive correlation between duration of OOS and 
HA and muscle power graded by MRC sum scores. (R=0.26 CI 0.04 to 0.40). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6  
 
R -0.39 CI -0.21 to -0.54 
Figure 3-6 Correlation between GBSD and the 
duration between date of onset of symptoms 
and hospital admission. 
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Mean duration between OOS and entry into study was 7 days. All the patients reached 
their peak disability within 4 weeks of entry into the study. This suggests that all the 
patients reached their nadir within 5 weeks of onset of symptoms. Only 3 patients 
deteriorated beyond 4 weeks of entry into the study and out of these three patients two 
had A-CIDP. 
 
Clinical recovery process (as defined by improvement in GBSD by 1 grade) started in 
18 % patients within the first week of entry into study and about 24 % patient within 4 
weeks of entry into the study. About 58 %patients did not have any functional 
recovery up to 4 weeks. While the frequency of sensory motor GBS was similar across 
the England and Scotland, there was significant difference between the frequency of 
MFS (England 6.3 % Vs 0% Scotland) and pure Motor GBS (12.7 % England Vs 25 % 
Scotland) patients across the Scotland and England.  
 
 
 
 
 
 
 
Figure 3-7 Correlation between MRC sum 
score and the duration between onset of 
symptoms and hospital admission.  
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3.5 Treatment patterns 
 
About 90 % of patients were treated with intravenous immunoglobulin (IVIG), and 
only 1.8 % patients received plasma exchange. Only two patients had received PE as 
the first line treatment. Reason for this was not clear in one patient recruited 
elsewhere, while in one patient recruited at local centre, PE was given due to concerns 
regarding renal failure.   About 8 % patients did not receive any treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
About 16 % of patients received 2nd course of immunotherapy. Out of 19 patients 12 
received second course of IVIG and 6 patients received PE. One patient had been 
concomitantly recruited into ICA GBS trial and had received either placebo or 
eculizumab. Six patients received the third course of treatment.  
 
Figure 3-8 Treatment patterns of GBS patients in the UK 
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3.7 Missing data: 
 
Most patients had well documented acute phase data. However about 20 % patients did 
not have 4 weeks outcome data, 25 % patients had 6 months missing data, and only 58 
% patients had 12 months outcome data collected. 
 
 
 
3.8 Discussion: 
 
This study represents the first prospective observational study since wider availability of 
immunotherapy in the UK. Previous population based studies were performed in 1988 and 
1998. (39,101) Although, randomised control clinical trials have been performed 
previously, it only included severely affected patients. In this study, adult GBS patients 
irrespective of their clinical severity were included. Our study continues to show 
slightly male predominant pattern with ration of 1.3/1.  
 
With regard to preceding infections, previous studies have shown that about 68 % of 
GBS patients have clinical or serological evidence of preceding infection within 4 
weeks prior to symptoms onset. In our study, about 78 % patients had antecedent 
infections within 8 weeks prior to GBS onset, this is consistent with biological 
plausibility.  The median time between OOS and antecedent infections was only 15 
days in our cohort, which suggests that in majority patients, with infectious trigger; 
this occurs in following 2 weeks time. The range of duration between OOS and 
antecedent infection was 0-62 days. One patient had symptom onset and onset of 
infection at the same time, this patient was diagnosed with Rubella infection at the 
time of GBS onset. This may need further clarification from the local investigator as 
the patient may have been infected prior to clinical symptoms onset due to 2 weeks 
incubation time. One patient had symptoms of URTI 62 days prior to onset of GBS 
which is slightly out in keeping with strict 8 weeks (56 days) definition. In most cases 
primary immune response initiates within 5-7 days of antigenic trigger and this 
followed by class switch and exponential rise in the concentration of antibodies. Since 
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the median time between most infections and OOW was 14 days, this can be well 
explained by antibody mediated pathogenesis; however why some patients took almost 
8 weeks to develop GBS after initial trigger needs further explanation. Further clinical 
–serological correlation studies will be very helpful to get better understanding of this 
issue.     
 
Clinically, GBS can be classified in to different variants. In a typical GBS, generalised 
ascending muscle weakness is a major feature and sensory symptoms are relatively 
minor component. In our cohort, 66 % patients had both sensory motor symptoms 
followed by 16 % patients had pure motor symptoms. Some patients characterised as 
“pure motor GBS” had abnormal sensory signs on examination. Whether these patients 
with subclinical sensory fibre involvement should be classified as sensory- motor or 
pure motor variants based on symptoms only needs further clarification and should be 
incorporated in the future studies. The current study protocol does not clarify this issue 
and hence patients were classified at examiners’ discretions. 
 
 Only 10 % patients with pure motor variants had cranial nerve involvement as oppose 
to 100 % patients with MFS and MFS-GBS variants and 49 % patients with sensory 
motor GBS. Frequency of respiratory muscle involvement was similar in both sensory 
motor and pure motor forms (17 % in pure motor GBS Vs. 20 % in sensory motor 
GBS). One patient with MFS- GBS overlap syndrome had respiratory failure. One 
patient with PCB variant required MV; however this well may be due to dysphagia 
rather than respiratory muscle involvement.  
 
CSF analysis is considered to be the part of routine diagnostic process in GBS. 
However at some centres this is not being performed routinely and diagnosis was made 
mainly on clinical grounds.  Our cohort continues to show previously well documented 
observation of cytoalbumin dissociation with mean CSF white cell count of 2.8/cu mm 
and raised mean CSF protein of 1.08 gm/L. One patient had CSF protein of 11 gm/L. 
In our study about 18.4 % patient did not have CSF studies performed and most of 
these patients had sensory motor GBS.CSF can be normal in GBS patients especially if 
it is performed early in the course. In our study, mean duration of OOW and CSF 
study was 4.6 days with a range of 0 to 13 days. About 29.8 % of patients had normal 
CSF studies. The mean duration of OOW and CSF study in this group was 3.5 days. 
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There was no statistical difference in duration of OOW and CSF study, between the 
groups of patients with elevated and normal CSF protein (3.5 days normal vs 5.3 days 
elevated CSF protein, P 0.79) 
 
Treatment of GBS has changed significantly in last 30 yrs. In a study performed by 
Winer et al in 1988, only 10 % patients had received PE and none of the patients 
received IVIG. (39) Subsequent population based study performed by Rees et al in 
1998 showed only 66 % patients received immunotherapy and out of these patients, 46 
% patients received IVIG as opposed to only 6 % patients received PE. This trend has 
clearly changed now and our cohort study showed that about 90 % patients received 
IVIG and only 1.8 % patients received PE. Out of 114 patients 24 had mild GBS and 
90 patients had severe GBS (defined by inability walk more than 10 meters 
independently). Sixteen out of 24 mild GBS patients (66.6 %)  received IVIG. This is 
an important finding as immunotherapy is generally not recommended in mildly 
affected GBS cases. Two out of 90 patients did not have treatment data recorded 
however all 88 severely affected patients received either IVIG or PE. One patient who 
did not receive any immunomodulatory treatment despite being unable to walk had 
MFS. This trend suggests that IVIG is the most commonly prescribed treatment in 
GBS patients. However, due to the cost of IVIG treatment and poor affordability of 
patients, this may not be the trend in developing world and it would be interesting to 
compare the results of our cohort with IGOS data from any other developing countries. 
One of the important findings from our study is that about 66.6 % of mildly affected 
GBS patients still being treated with immunotherapy. Whether this makes any 
difference in overall outcome requires further analysis and if this is the case, it would 
have significant implication on current treatment practice.   
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3.9 Conclusion: 
 
 
Demographic description of our cohort shows that sensory-motor GBS remains to be 
the major clinical phenotype in the UK. Rate of clinical antecedent infections remains 
very consistent at 78 % especially preceding 8 weeks of GBS onset and this requires 
further serological correlation studies to establish the link between antecedent 
infections and type of GBS. Although, CSF studies are routinely performed in most 
centres, at some centres this is not being done routinely. While IVIG has replaced PE 
as a first line treatment for GBS in the UK, it is also being prescribed for mild cases 
too and whether that translates in to any clinically meaningful outcome remains to be 
seen and requires further analysis, 
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4.1 Introduction: 
 
Despite immunotherapy GBS remains a disabling disorder in about 20 % patients and 
about 5 % patients die. These data comes from various clinical trials and some 
prospective observational studies performed in western world. Outcome in developing 
world may not be the same. One of the purposes of IGOS was to study GBS patients 
across the wide geographical areas including some developing countries. IGOS will 
provide us a unique opportunity to compare outcomes in various geographical areas. 
Since this data is still being collected at the time of writing this thesis we sought to 
analyse the outcome of IGOS UK cohort. 
 
4.2 Mortality 
 
Out of 78 patients, who had 12 months outcome 4 died, with an overall mortality rate 
of 5.1 %. Out of 4 deaths, one patient died of aspiration pneumonia, one due to 
ischemic colitis, and one due to peritonitis. Cause of death was unclear in the fourth 
patient. Three patients died within 4 weeks of entry in to the study and one patient died 
in the recovery phase. 
 
 
 
4.3 Respiratory failure 
 
Twenty-one out of 114 patients (18 %) required mechanical ventilation (MV). Out of 
21 patients, 14 patients (66 %) required MV within 2 weeks of symptoms onset, 5 
patients (23.8 %) required MV within 3 weeks of symptoms onset and only 2 patients 
required MV within 6 weeks of symptoms onset. Only 2 patients continue to require 
MV beyond 6 months. Out of 21 patients 10 had their 12 months outcome data 
available, and 2 out of 10 patients died with an overall mortality of 20 %.  
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4.4 Disability 
 
In order to compare the outcomes of our current study with previous studies we used 
proportion of patients achieved a particular functional outcome at 4 weeks, 6 months 
and 12 months as the primary outcome measures. 
 
We first divided all patients in two categories; Mild GBS as defined by GBSD < 2 and 
Severe GBS cases as defined by GBSD > 3 at the entry point into the study. Out of 
111 cases 89 had severe GBS and 22 had mild GBS. 
 
 
 
 4.4.1 Outcome of severely affected GBS cases: 
 
Proportion of severe GBS patients improved by one grade on GBSD scale at 4 
weeks: 
 
Most of the clinical trials have used this outcome as a primary end point. In our cohort, 
out of 89 (79 %) severe GBS cases 17 patients did not have 4 weeks outcome data and 
these cases were excluded from analysis. Thirty-four patients (45.9 %) out of 72 cases 
improved by 1 grade on GBSD at 4 weeks. All these patients were treated with either 
IVIG or PE. 
 
Ability to walk without support at 4 weeks: 
 
 
Although most clinical trials have used “proportion of patients improved by 1 GBSD” 
as the primary endpoint, as clinicians what we need is the information about prediction 
of ability to walk as that what matters to most of the patients. In our cohort out of 72 
patients, 24 (33.3 %) were able to walk independently at 4 weeks.
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                 Ability to walk without support at 6 months: 
 
 
Out of 89 severely affected cases 70 patients had 6-month outcome data. All together 
78 % patients were able to walk independently at 6 months time with standard 
treatment. 
 
 
 
Ability to walk without support at 12 months: 
 
 
Only 59 severely affected patients had 12 months outcome and about 85 % patients 
were able to walk unaided at this time point. 
 
Complete Recovery at 12 months: 
 
 
19 out of 59 patients (22 %) had complete neurological recovery as defined by GBSD 
of 0. About 32 % patients continued to have minor symptoms and 32 % patients were 
able to walk independently but unable to run. 
 
 
 
 
 
 
4.4.2 Outcome and subgroup analysis of severely affected GBS cases: 
 
We divided severe GBS in to two further sub groups moderate GBS defined by GBSD 
of 3 at entry and severe GBS defined by GBSD of 4 and 5 at entry.  
 
Moderate GBS (GBSD of 3): 20 patients had entry GBSD of 3. Out of 20 patients, 16 
patients had their 4 weeks outcome data available. Eight out of 16 patients (50%) 
improved by 1 grade on GBSD, similarly 8 out of 16 (50%) patients were able to walk 
independently at 4 weeks time. Eighteen out of 19 patients (94.7 %) were able to walk 
independently at 6 months time and almost all 19 patients (100 %) were able to walk 
independently at 12 months time. Only 36.8 % patients had complete recovery defined 
by GBSD of 0. 
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Severe GBS (GBSD of 4 and 5): Out of 69 patients, 56 patients had their 4 weeks 
outcome data available. Twenty six out of 56 patients (46.4 %) improved by 1 grade 
on GBSD, 16 out of 56 (28.5 %) patients were able to walk independently at 4 weeks 
time. Thirty six out of 52 patients (69.2 %) were able to walk independently at 6 
months time and 33 out of 45 patients (69.2 %) were able to walk independently at 12 
months time. Only 15. 5 % patients had complete recovery defined by GBSD of 0. 
 
                  Table 4-1 Subgroup analysis of moderate and severe GBS 
 Moderate GBS Severe GBS P Value 
Improvement by 1 
grade on GBSD at 4 
weeks  
8/16 26/56 0.802 
Proportion of patients 
able to walk 
independently at 4 
weeks 
8/16 16/56 0.1096 
Proportion of patients 
able to walk 
independently at 6 
months 
18/19 36/52 0.025* 
Proportion of patients 
able to walk 
independently at 12 
months 
19/19 33/45 0.012* 
Proportion of patients 
with complete recovery 
at 12 months  
7/19 7/45 0.060 
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4.4.3Outcome of mild GBS cases: 
 
All together we had 24 mild GBS cases (21 %). Two mild GBS cases had acute onset 
CIDP and they were excluded from analysis. Amongst 22 cases, 3 had GBSD of 1 and 
they were not treated with IVIG, out of the rest of 19 patients, 14 were treated with 
IVIG. Out of 19 cases, two patients had clinical deterioration within the first week of 
entry. 
               
              Outcome at 4 weeks: 
 
 
Fourteen patients with GBSD of 2 had outcome data available at 4 weeks. Out of 
fourteen patients, 3 patients did not receive IVIG and 11 patients received IVIG. Only 
one patient out of 3 had improvement of more than 1 grade on GBSD (33 %) as 
opposed to 54 % patients in treatment group had improvement of more than 1 grade at 
weeks suggestive of faster recovery. 
 
Outcome at 6 months: 
 
 
Only 1 out of 9 IVIG treated patients had complete recovery (11 %) while none of the 
patients in non-treatment group had complete recovery. 
 
Outcome at 12 months: 
 
This analysis was confounded by very small numbers of patients. Altogether 10 
patients had outcome data available at 12 months. All the patients with entry GBSD of 
1 had complete recovery. While patients with entry GBSD of 2, 20 % had complete 
recovery in IVIG treated group as opposed to 50 % patients had complete recovery in 
non-treatment group.
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4.5 Quality of life measurement: 
 
Apart from mortality and mobility, outcome of GBS patients can be affected by 
various other determinants such as pain, fatigue, functional impairment related to 
upper limb disabilities and mental health. (102) All these factors in combination can 
affect quality of life (QoL) in GBS patients. In this study we measured QoL using 
newly developed preference based generic tool EQ-5D-5L. The tool divides health 
related QoL in to five dimensions; Mobility, self care, usual activity, pain/discomfort 
and anxiety/depression. It also includes a visual analogue scale (VAS), ranges from 0 
(worst health) to 100 (best health), which is self reported by patients depending on 
their perception of overall health status.  
All together 67 patients had EQ-5D-5L and VAS data recorded at 12 months time. 
Response level frequencies for each dimension are shown in the table 4.2.  
 
Difficulty with usual activity was the most problematic domain amongst all. Overall, 
62.12 % patients reported some degree of problem with their usual activities at 12 
months. This was followed by pain with 54.55 % patients reported slight to severe pain 
at 12 months time. Mobility continued to remain as a problem in about 51.52 % 
patients. Only 9.9 % patients reported severe problem with their mobility. This was 
followed by anxiety and depression with 33.33 % patients reported slight to severe 
mental health issues at 12 months time. Self care was the least affected domain of all, 
with only 27.27 % patients had problem with this domain at 12 months time.
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Table 4-2  Percentage of participants reporting level 1-5 in each EQ-5D-5L dimension at 12 months 
EQ-5D-5L dimensions 
Distribution of 
response Percentage frequency 
Mobility   
No Problem 32 48.48 
Slight 14 21.21 
Moderate 12 18.18 
Severe 6 9.09 
Unable to walk 2 3.03 
   
Self care   
No Problem 48 72.73 
Slight 6 9.09 
Moderate 8 12.12 
Severe 3 4.55 
Unable to walk 1 1.52 
   
Usual Activity   
No Problem 25 37.88 
Slight 18 27.27 
Moderate 15 22.73 
Severe 6 9.09 
Unable to walk 2 3.03 
   
Pain   
No Pain 30 45.45 
Slight 17 25.76 
Moderate 15 22.73 
Severe 4 6.06 
Extreme 0 0.00 
   
Anxiety/Depression  
No Problem 44 66.67 
Slight 14 21.21 
Moderate 6 9.09 
Severe 2 3.03 
Extreme 0 0.00 
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 Relationship between each domain and overall QoL visual analogue score:  
 
In general, QOL VAS represents patient’s own view of their health and therefore it 
gives very useful information about wider dimensions of patients’ health other than 5 
dimensions of EQ-5D-5L.(103)   In order to identify most important domain of QoL 
affecting the perception of good quality of health of GBS patients, we analysed 
response level frequencies and compared with QOL VAS. Patients were divided in to 
“no problem” and “slight to extreme” groups. Mean QoL VAS calculated using 
unpaired t tests. As described in table only problems with “usual activity” was 
associated with statistically significant difference in QOL VAS suggestive of most 
important domain remained affected at 12 months time in GBS patients responsible for 
poor perception of quality of health in this group of patient.  
 
 
                                        
 
                                    Table 4-3 Relationship between EQ-5D-5L domains and QoL VAS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 
 
Mean QoL VAS 
No Yes P value 
Mobility 
71.06 88.72 0.8525 
Self Care 
85.1 65 0.5648 
Usual 
Activity 
91.72 72.24 0.0415 
Pain 
90.47 70.58 0.2272 
Anxiety/ 
Depression 
84.2 70.45 0.3812 
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4.6 Comparison between GBSD, MRC sum scores, ONLS and 
RODS 
Sensitivity of GBSD and MRC sum score in detecting small clinical change in 
muscle strength: 
 
We compared MRC sum scores and GBSD to ascertain the sensitivity of both scales in 
detection of small clinical change. As described in figure 4.1, there was a strong 
negative correlation (R = -0.74, CI -0.7962 to -0.6723, P <0.0001) between GBSD and 
MRC sum scores, i.e. Higher the GBSD lower the MRC sum scores. However the 
variation in MRC sum scores was high in GBSD categories 4 and 5, which suggests 
that GBSD is not very sensitive measure to detect small change in muscle strength. 
However MRC scum score also has disadvantage for example MRC sum score can be 
normal in patients with pure sensory GBS as well as MFS where patient can be 
severely disabled due to ataxia. Similar negative correlation observed between rasch 
MRC sum scores and GBSD (R= -0.71, CI 0.77-0.64, P < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1 GBSD Vs MRC sum score in detecting 
small clinical changes  
Figure 4-2 GBSD Vs Rasch MRC sum score  
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Comparison between GBSD, ONLS and RODS: 
 
Similarly we compared GBSD scale with ONLS and RODS and as shown in Figure 
4.3 and 4.4 respectively, an increasing value of GBSD was broadly associated with a 
higher value of ONLS though the range of ONLS values obtained for each participant 
for the lower GBSD categories was wider implying a weaker relationship between the 
two measures at lower GBSD than higher GBSD categories .This analysis suggests 
that in acute setting MRC sum score and rasch MRC sum score are very useful in 
detecting minimal change in clinical condition while RODS is useful in capturing wide 
range of disabilities in the later stage of the disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3 GBSD vS ONLS 
Figure 4-4 GBSD Vs RODS 
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4.7 Discussion:  
 
IGOS is the first prospective multi centre observational study looking at various 
outcomes in GBS spectrum disorders. As part of this study, we had an opportunity to 
study various outcomes in GBS patients recruited in the United Kingdom between 
2012 to 2015. 
 
Our study showed that despite wider availability of immunotherapy, GBS mortality 
rate has not changed significantly. This clearly highlights the need for more effective 
therapeutic options in the area. While aspiration pneumonia remains to be an 
important cause of death, in our study two patients died due to gastroenterological 
complications namely ischemic colitis and peritonitis. While venous thromboembolic 
events are common complication of GBS due to immobility and prothrombotic nature 
of IVIG treatment, arterial thromboembolic complications have not been widely 
reported in the literature. Whether this was a coincident or was related to GBS remains 
to be seen. 
 
Compared to previous studies, the rate of patients requiring MV was slightly lower at 
18 % and those who required MV, they did so in the first 3 weeks of GBS symptoms 
onset. This finding suggest crucial role of respiratory monitoring in GBS patients 
especially during the first 3 weeks. Only around 10 % patients required MV after 3 
weeks of symptom onset. Mortality rate was higher in patients requiring MV 
compared to overall mortality rates in GBS patients (20 % vs 5%). 
 
With regard to disability, we first compared the percentages of severly affected GBS 
patients improved by 1 grade on GBSD at 4 weeks. This is the most common primary 
outcome measure has been used in previous clinical trials involving sever GBS 
patients. Our study showed that about 45.9 % patients had improvement in their 
GBSD by 1 grade. This is slightly lower than average of 59.4 % of five studies 
involving PE, however better than average of 35 % of patient with no treatment. 
 
In our study, 33 % severely affected GBS patients were able to walk independently at 
4 weeks, 78 % were able to walk independently at 6 moths and 85 % patients were 
able to walk independently at 12 months. These rates are very much similar to findings 
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from previous clinical trials. Only 22 % patients had complete recovery at 12 months 
time, these findings suggest that long term outcome of severely affected GBS has not 
changed significantly. 
 
Analysis of outcomes mildly affected GBS was somewhat cofounded by small number 
of patients and also by the treatment variation. However, our study showed that short 
term outcome at 4weeks was slightly better in patient who had received 
immunotherapy. However, the long term outcome was better in patients who did not 
receive any immunotherapy. This finding requires further study with a larger cohort. 
 
Analysis of QoL data using EQ-5D-5L scale showed that although mobility and pain 
remained to be major issues at 12 months, inability to perform usual activity was the 
most commonly affected dimension of life, which also resulted in perception of poor 
QoL to GBS patients. 
 
With regard to available outcome measures our analysis of comparison of impairment 
scales and outcome scales showed that MRC sum score was better at capturing 
minimal clinical change in acute phase of the disease compared to GBSD scale. 
However, we recommend using both in acute phase, as MRC sum score is very much 
dependent on muscle weakness, which is absent in sensory/ataxic GBS cases. For the 
recovery phase monitoring although ONLS captures wide range of disabilities, due to 
its ceiling effect and non linearity we recommend using RODS.  
 
   
4.8 Conclusion: 
 
IGOS is the first observational study conducted after almost 30 years, providing an 
excellent opportunity to study GBS outcome in the UK.  Previous study conducted by 
Winer et al showed mortality rate of 13 %, about 67 % patients had complete recovery 
at 12 months and 20 % patients remained significantly disabled. Out of 100 patients 
only 10 % patients received plasma exchange and about 12 % patients received steroid 
treatment.  
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Our study shows that there has been significant change in the mortality rates ( 13 % vs 
5.1%) due to wider  the availability of immunotherapy. However, the long term 
outcome at 12 months has not changed significantly highlighting the need for better 
therapeutic options other than broad spectrum immunotherapy such as IVIG.  
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Chapter 5 Role of EPS in 
GBS 
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5.1 Introduction 
 
Traditionally GBS was considered to be a demyelinating disorder. However after 
identification acute motor axonal variants, this view has been challenged. 
Electrophysiologically, GBS now is being classified into two variants - axonal or 
demyelinating form; depending on the nerve fibre involvement. Axonal variants can be 
further reclassified into acute axonal motor (AMAN) and acute motor and sensory 
(AMSAN) variants. Recognising these subtypes is important as different subtypes may 
have different immunopathological basis and therefore their treatments and prognosis 
may also be different. Thus electrophysiology (EP) may have both diagnostic as well 
as prognostic value. 
 
5.1.1 GBS electrophysiological diagnostic criteria 
 
Lambert and Mulder published the first report of EP abnormalities in GBS patients in 
1964. (104)The study showed that about 14 % of the patients had normal studies, 61 % 
of the patients had abnormal motor conduction velocities (CV) and about 25 % of the 
patient had prolonged distal motor latencies (DML). At this time motor nerves 
conduction slowing in distal segment along with prolonged latencies were considered 
the criteria for demyelination. In 1976, King and Ashby first described that 
measurement of F wave abnormality (using the technique developed by Kimura) could 
represent underlying proximal demyelination and can be used as an early diagnostic 
marker of the disease. (105,106) 
 
The first consensus based EPS criterion was published by Asbury and colleagues in 
1978. (48) In their report they described following EPS features; 1) CV is usually less 
than 60 % of normal; 2) about 80 % of patients have motor conduction slowing or 
block at some point during the course of illness; 3) DML can be prolonged up to three 
times of normal and 4) about 20 % of patients have normal studies. 
 
In 1985, Albers and colleagues reviewed sequential EPS from 180 GBS patients and 
described normal sural and abnormal median nerve findings pattern. In this report they 
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also proposed quantitative cut off values for CV, DML and F wave latency. 
 
 
 
 
 
 
 
 
 
 
 
In 1990, Cornblath et al proposed a new criteria set for detection of primary 
demyelination.(49). These criteria required minimum of three features of 
demyelination as oppose to only one required in Albers criteria, making it more 
specific but less sensitive for GBS diagnosis. (107,108) 
 
Recognition of axonal GBS cases in 1995, required researchers to amend previously 
existing criteria, and therefore Ho et al published a new criteria, which included 
parameters for primary axonal degeneration.(109) Hadden et al further modified this 
criteria and proposed a new set of criteria to diagnose AIDP and AMAN. (110) One of 
the major differences between these two criteria was consideration of CB in Hadden’s 
criteria while it was not considered in the criteria proposed by Ho. Also Ho et al 
considered temporal dispersion as one of the features of demyelination while Hadden 
et al did not include TD in their criteria. 
 
Criteria for AMSAN have been described. Rees et al first in 1995, and subsequently 
Capasso et al in 2011 described following EP features; 1) No evidence of 
demyelination 2) dCMAP <80 % of lower limit of normal in motor nerves 3) reduction 
in sensory nerve action potential <50 % of normal in at least two nerves. (111,112) 
 
 
Figure 5-1 GBS electrodiagnostic criteria (Alber et al 1985) 
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5.1.2 Pitfalls in existing EP criteria 
 
One of the major issues involving EPS in GBS is that there is no consensus based, 
universally accepted criteria. AIDP criteria vary in terms of cut off values for various 
demyelinating parameters. For example for CV, various values ranging from 60 % to 
95 % of lower limit of normal have been used in GBS literature. The Cut off value of 
60 % has been used in various studies based on assumptions that slowing in CV below 
60 % occurs due to demyelination based on some studies performed on amyotrophic 
lateral sclerosis and Charcot Marie Tooth diseases patients.(113) The evidence for 
other cut off values are not available in the literature. As a result of different cut off 
values used in different criteria, diagnostic sensitivity of GBS varies depending on the 
criteria used. Alam et al studied 43 american GBS patients and their EPS and 
compared the diagnostic sensitivities of six different available criteria and found that 
sensitivities varied from 21 % to 72 %. (105) In a similar study performed on Indian 
cohort of 51 GBS patients, Kalita et al found that diagnostic sensitivities of different 
criteria varied from 39 to 88 %. (108) 
 
Criteria for AMAN and AMSAN have been proposed, however they were based on 
traditional view that axonal GBS represents underlying simple axonal degeneration. 
Recently,  Kuwabara and colleagues have challenged this view. (114) In their study, 
they demonstrated that three AMAN patients with positive anti ganglioside antibodies 
had low distal CMAPs and on repeat studies CMAPs became normal. Similarly, in 
another group of antibody positive patient, who were classified as having AIDP based 
on only prolonged DML or only CB on the first EPS, complete reversal of EPS 
abnormality occurred in the repeat study, without development of any TD or 
polyphasia, which are the markers of re-myelination. Patients in both groups had 
almost complete clinical recovery. It is likely that these patterns of reversible EP 
abnormalities in antibody positive patients with subsequent complete clinical recovery 
reflect underlying functional rather than structural block due to Na-channel 
dysfunction. (115) Interestingly, these features were not seen in antibody negative 
AIDP and AMAN patients with on-going degeneration and poor clinical recovery. 
Hiraga et al performed a similar study of 25 antibody positive GBS cases and found 
that in some patients with complete recovery had reversible isolated F wave 
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abnormality. (114) 
 
Above studies suggest three different EP patterns in axonal GBS; 1) Simple wallerian 
axonal degeneration 2) transient CB in intermediate or conduction slowing at distal 
motor nerve terminals reflected by prolonged DML and 3) transient prolongation of F 
wave latency. Considering these features Uncini and Kuwabara have coined a new 
terminology calling it ‘Reversible Conduction Failure’ (RCF). (117) These patterns 
also reflect in the clinical recovery pattern seen in axonal GBS; as some axonal GBS 
with typical wallerian degeneration make poor recovery while others with RCB make 
almost complete recovery. Not only that, these studies also highlight the importance of 
serial EPS, in order to identify appropriate GBS subtype, as some of these features can 
be seen in otherwise classical AIDP in the early stages and these patients can be 
wrongly classified as having AIDP based on single EPS. 
 
Stressing importance of serial nerve conduction studies, Uncini et al performed a study 
of 55 GBS patients with serial EPS recording, using two well-described criteria.(118) 
The study showed that about 65-67 % of patients were classified as having AIDP, 18 
% were classified as having axonal GBS and 14-16 % were classified as equivocal on 
the first examination. On repeat examination, 24 % of the patients’ EPS classification 
changed; only 58 % had AIDP, 38 % had axonal GBS and only 4 % of patients had 
equivocal EPS. This study highlights the critical role of serial nerve conduction studies 
in identification of final GBS subtypes, which is again very crucial for correct 
serological-clinical-EPS correlation. However performing serial EPS can be time 
consuming and impractical in some clinical settings. Also a recent study performed by 
Rajabally et al showed that the demyelinating cut off values used in current EP criteria 
(Ho and Hadden) may partly be responsible for incorrect EP diagnosis of GBS. (122) 
Using their modified criteria Rajabally et al showed that a single EP study may be 
adequate to establish final EP diagnosis. 
 
IGOS provides a unique opportunity to study these issues in detail. We conducted a 
pilot analysis of prospectively collected EP data at a single centre (Glasgow). 
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5.2 Aims 
 
The aim of this study was to analyse prospectively collected EP data from a single 
centre (Glasgow) to determine whether using modified EP criteria developed by 
Rajabally et al is sufficient to achieve the final EP diagnosis. We also compared 
various criteria to determine sensitivity of each criterion and finally performed a 
clinical- electrophysiological correlation of entire IGOS UK database. 
 
5.3 Methods 
 
Patients: 
 
Electrophysiological data from 32 prospectively recruited GBS patients at local centre 
(Glasgow, Scotland) was analysed. Out of 32 patients 24 patients had repeat EP 
studies performed. At the local centre we first circulated IGOS EPS protocol to all five 
neurophysiology consultants and data was collected using this protocol when feasible. 
Electrophysiological examination was performed at two separate time points in 24 
patients: the first within 7 days of admission or registration in IGOS, and the second at 
four weeks after admission or registration in IGOS. The data included sensory studies 
in legs and arms (3-4 nerves), motor studies with F wave (3-4 nerves), tibial H-reflexes 
and EMG of a proximal and distal muscle in an arm and leg. Normative data and 
pictures of the waveforms were also being included in the report. Following 
parameters were measured: conduction velocities (CV), distal motor latencies (DML), 
distal and proximal compound muscle action potential (dCMAP and pCMAP)), 
minimum F wave latencies, sensory nerve distal latency and sensory nerve action 
potential (SNAP). When possible, data was collected from non-dominant side.  
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Normal values for local lab (Glasgow): 
For the analysis, I compared different criteria using following normative local lab 
(Glasgow) values: 
 
                    Table 5-1 Electrophysiology normal values (Glasgow lab) 
 
Median Ulnar C Peroneal Tibial 
CMAP 4 6 2 4 
DML 4.1 3 6.1 6.1 
CV 48 48 40 40 
F 30 31 55 55 
 
Electrophysiological criteria: 
 
Following EP diagnostic criteria were assessed. 
 
Alber Criteria: 
 
                   
                  Table 5-2 Alber’s electrodiagnostic criteria set 
AIDP 
Evaluation should satisfy at least three of the following in motor nerves 
 MCV < 75 % LLN ( two or more nerves) 
 DML > 130 % ULN ( two or more nerves) 
 F wave latency >  130 % ULN ( one or more nerves ) 
 Proximal CMAP/distal CMAP ratio < 0.7 ( one or more nerves) 
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Hadden criteria: 
 
 
                Table 5-3 Hadden electrodiagnostic criteria set 
AIDP 
 At least one of the following in each of at least two nerves, or at least two of the 
following in one nerve if all others are inexcitable and dCMAP ≥ 10 % LLN 
 
o Motor conduction velocity < 90 %LLN (85 % if dCMAP is < 50 % LLN) 
o Distal Motor Latency >110 % (> 120 %  if dCMAP is < 100 % LLN) 
o Amplitude of proximal CMAP /dCMAP ratio < 0.5 and dCMAP ≥ 20 % 
LLN 
o F wave latency > 120 % 
AMAN 
 None of the features of demyelination in any nerves defined as above except one 
demyelinating feature allowed in one nerve if dCMAP is < 10 % LLN 
 dCMAP < 80 % LLN in at least two nerves 
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Rajabally criteria:  
 
                  Table 5-4 Rajabally’s ectrodiagnostic criteria set 
Normal 
All the following in all nerves tested  
 DML ≤ 100 % ULN 
 F wave latency ≤ 100 % ULN 
 MCV ≥ 100 % LLN 
 Distal CMAP ≥ 100 % LLN 
 Proximal CMAP/distal CMAP ratio > 0.7 (excluding tibial nerve ) 
AIDP 
At least one of the following in at least two nerves 
 Motor conduction velocity < 70 %LLN  
 Distal Motor Latency >150 %  
 F wave latency > 120 % ULN or > 150 %  ULN ( if dCMAP < 50 % of 
LLN) 
OR 
Absent F waves in two nerves with dCMAP ≥ 20 % LLN with an additional 
parameter in one  other nerve  
OR 
pCMAP/dCMAP ratio < 0.7 in two nerves with additional parameter in one other 
nerve   
AMAN 
None of the features of demyelination in any nerves defined as above (except one 
demyelinating feature allowed in one nerve if dCMAP is < 10 % LLN) and at least 
one of the following  
 dCMAP < 80 % LLN in at least two nerves 
 Absent F waves in two nerves with dCMAP ≥ 20 % LLN in absence of  
any demyelinating  parameter in any other nerve 
 pCMAP/dCMAP ratio < 0.7 in two nerves  
 Absent F waves in ONE nerves with dCMAP ≥ 20 % LLN  
       OR  
pCMAP/dCMAP ratio < 0.7 in ONE nerves   
with in addition  
dCMAP < 80 % LLN in one other nerve  
Inexcitable 
If dCMAP absent in all nerves or present in only one nerve with dCMAP < 10 % 
LLN 
Equivocal 
Abnormal range findings however not fitting criteria for any other group 
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In order to identify sensitivity of different EP criteria, first data was entered into a 
standard template using excel software. This data was probed using different sets of 
EP criteria using local normal values. Statistical analysis was performed using SPSS 
software when required. 
 
For clinical- EP correlation, we collected clinical and electrophysiological data from 
IGOS website from the patients recruited at 15 different centres in the UK, between 
May 2012 and January 2015. Clinical characteristics such as sensory motor or pure 
motor or MFS variants were identified and correlated with their electrophysiology 
record. Statistical analysis was performed using fisher’s exact test. 
 
5.4 Results 
 
 
I included 32 GBS patients at the local centre. There were 19 male and 13 female 
patients with a mean age of 58.3 years ( range 28-87 years). Median interval between 
the symptom onset and EPS was 8 days (range 1-21 days). 
 
5.4.1 Sensitivity of existing criteria: 
 
Since Albers’ was the most commonly used criteria for the early detection of AIDP 
cases, we first probed EPS database (Glasgow) using this criteria to see how many 
patients met the EPS criteria for AIDP. These criteria allowed one of the 
demyelinating abnormalities in two motor nerves. Using these criteria, 62.5 % patients 
could be diagnosed with AIDP.  
 
We then probed the database using Dutch GBS study criteria, and found that 25 out of 
32 patients (78 %) could be diagnosed as having AIDP.  Since both Albers and Dutch 
GBS study group criteria did not define axonal variants, we probed our data using 
Hadden criteria, which included axonal variants. Using Hadden criteria 78 % patients 
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met AIDP criteria. Interestingly none of our patients were classified as having axonal 
GBS.  
 
               Table 5-5 Sensitivity of different GBS EP criteria set 
GBS Electrodiagnostic criteria               AIDP Equivocal Normal 
Alber  81.3 % 12.5 % 6.3 % 
Dutch GBS 78 % 15.6 % 6.3 % 
Hadden 78 % 15.6 % 6.3 % 
 
 
 
 
As highlighted in the table 5.6, when I performed clinical correlation, 44 out of 
75 patients with sensory motor GBS had AIDP, 2 patients with clinical Sensory 
Motor GBS were classified as having AMAN on EPS. Repeat study performed 
in 3 weeks in one of these patients continued to show findings in keeping with 
AMAN with on-going active denervation.  
 
Out of 19, clinically pure motor GBS cases, 7  were classified as having AIDP 
and 8 patients were classified as having  AMAN and 1 patient was classified as 
having equivocal on EPS.  
 
Out of four MFS patients three patients had normal EPS, and EPS was not 
performed in one patient. Three patients out of nine patients with MFS-GBS 
overlap syndrome were classified as having AIDP and 3 had equivocal 
findings. One patient with pure sensory GBS and one patient with pure ataxic 
GBS were classified as having AIDP while all patients with acute onset CIDP 
patients had typical findings of AIDP on electrophysiological studies. 
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5.4.2 Does EP characteristics change with serial studies using conventional 
Hadden criteria or a single study using modified Rajabally criteria suffice? 
 
 
To address above question I first analysed the EP data of 32 patients from the 
local centre (Glasgow) using both Hadden and Rajabally criteria. As 
highlighted in table 5.5 using Hadden’s criteria set 81.3 % patients were 
classified as having AIDP, 12.5 % were classified as having equivocal and 6.3 
% patients were classified as having normal electrophysiology. Application of 
Rajabally criteria showed 56.3 % patients having AIDP, 21.9 % patients having 
AMAN, 15.6 % patients having equivocal and 6.3 % patients had normal 
studies. 
 
 
 
 
 
 
                 Table 5-6 Comparison of Hadden and Rajabally criteria in 32 patients with a single study 
 AIDP AMAN Equivocal Normal 
EPS Criteria     
Hadden 81.3 % 0 % 12.5 % 6.3 % 
Rajabally 56.3 % 21.9 % 15.6 % 6.3 % 
P Value 0.03 0.005 0.72 1 
 
Analysis of serial EP data using Hadden’s criteria set: 
Analysis of serial EP data collected from 24 patients showed that using 
Hadden’s criteria 83.33 patients were classified as having AIDP, 8.33 % 
equivocal and 8.33 % had normal study on the 1st EPS. Repeat EP analysis of 
this cohort using the same criteria proportion of AIDP patients decreased to 
62.5 % and about 20.8 % patients were identified as having AMAN. The 
classification shift occurred mainly in AIDP group and 5 (20 %) patients who 
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were initially classified as having were reclassified as AMAN (4 patients) and 
Equivocal (1 patient). On the repeat study, the proportion of equivocal cases 
was increased to 12.5 % and the proportion of normal EPS reduced to 4.1 %. 
 
EP classification shift occurred in 29 % cases and mostly in AIDP cases (71 
%). Out of 5 AIDP cases in which classification shift occurred, 4 cases were 
classified as having AMAN and 1 case was classified as having equivocal. 
Overall, there was a statistically significant proportion of patients changed the 
classification to AMAN (P 0.01). 
 
 
 
 
 
 
 
 
                Table 5-7 Comparison of Hadden and Rajabally criteria in 24 patients with serial studies 
 AIDP AMAN Equivocal Normal 
EPS Criteria     
Hadden-1 83.33 % 0 % 8.33 % 8.33 % 
Hadden-2 62.5 % 20.8 % 12.5 % 4.1 % 
P value 0.10 0.01 0.60 0.54 
Rajabally-1 54.1 % 20.8 % 12.5 % 12.5 % 
Rajabally-2 54.1 % 16.6 % 20.8 % 8.3 % 
P value 1 0.74 0.44 0.63 
 
 
Analysis of serial EP data using Rajabally’s criteria set: 
Analysis of serial EP data collected from 24 patients showed that using 
Rajabally’s criteria 54.1 % patients were classified as having AIDP, 20.8 % as 
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AMAN, 12.5  % as equivocal and 12.5  % as normal on the 1 st EPS. 
Importantly, the proportion of the patients classified as having AMAN with 
Rajabally’s criteria on the first study was similar on the repeat studies 
performed using Hadden’s criteria.     
 
Repeat EP analysis of this cohort using the same criteria proportion of AIDP 
patients remained the same at 54.1 % and about 16.6 % patients were identified 
as having AMAN. The classification shift occurred mainly in AMAN and 
normal group where one patient in each group was reclassified as having 
equivocal study. 
 
EP classification shift occurred in 25 % cases (total 6 out of 24 cases). Two 
cases of AIDP became equivocal and 2 equivocal cases became AIDP. One 
case classified as normal changed to equivocal and one AMAN case changed to 
equivocal on the repeat testing. However, overall proportions of each 
classification remained the similar with no statistical differences.  
 
 
Comparison between 2
nd
 Hadden and 1
st
 Rajabally study: 
We then compared 2
nd
 EP results using Hadden criteria and 1
st
 EP results using 
Rajabally’s criteria to determined whether single study using Rajabally is 
sufficient to achieve final EP diagnosis.  
                 Table 5-8 Compariosn between Hadden-2 and Rajabally criteria 
 AIDP AMAN Equivocal Normal 
EPS Criteria     
Hadden-2 62.5 % 20.8 % 12.5 % 4.1 % 
Rajabally-1 54.1 % 20.8 % 12.5 % 12.5 % 
P Value 0.55 1 1 0.29 
 
Our results showed that there was not any statistically significant difference in 
the proportion of each EP subtype.  
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5.5 Discussion: 
 
Above findings suggest that clinical variants are not good discriminator for underlying 
EP abnormality and highlight the pivotal role of EPS for correct sub classification of 
GBS patients. Electrophysiological demyelinating GBS cases can present with various 
clinical subtypes including ataxia, pure motor, pure sensory and sensory motor GBS. 
Our study confirms the earlier finding that EP remain normal in most MFS cases and if 
the EP becomes abnormal they most likely to have GBS-MFS variant. However, this 
analysis was performed on the data collected from IGOS website and also on basis of 
single EPS and therefore further clinical-electrophysiological analysis using normative 
values from individual lab will be very useful in order to confirm this finding.  
 
 Our study also highlights the drawback of existing EP criteria (including the most 
widely used Hadden’s criteria) showing variation in identification of various EP 
subtypes especially if the study is performed early in the course. Interestingly, without 
even considering “RCF” Hadden’s criteria failed to identify any AMAN cases when 
EP is performed early in the course. However on the serial study, EP shift occurred in 
about 29 % cases, mostly AIDP cases. This result confirms the earlier finding that 
existing Hadden’s criteria is not sufficient for the identification of final EP subtype, 
especially performed early in the course and serial EP is required. 
 
However, when we applied Rajabally’s criteria to first set of EP results, the proportion 
of each EP subtype was similar to the proportion identified by serial studies using 
Hadden criteria and therefore provides further support to the notion that using different 
demyelination cut off values and considering RCF, single EP study, even performed 
early is the course is sufficient to achieve final EP diagnosis.  
 
Having“gold standard” EP criteria although sounds ideal but practically may not 
possible for variety of reasons. As shown in our study, even in genuine cases of GBS, 
in about 4-8 % cases, EP remains normal, even after 3 weeks. Similarly, due to RCF, a 
proportion of patients including AMAN cases become normal and therefore 2 nd study 
also cannot be used as a gold standard. In proportion of cases, demyelination occurs 
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quite late in the clinical course which makes serial EPS even more challenging and 
therefore unhelpful. Demyelination, primary axonal degeneration or secondary 
degeneration is pathological diagnosis and since biopsies are rarely performed 
nowadays, EP is being used as surrogate marker to identify and sub classifies GBS 
into pathological categories. Also it is hard to believe that a single nerve can have only 
either demyelinating or axonal changes, considering the fact that inflammatory 
changes are patchy it is quite possible that EP may not be sensitive enough to capture 
all underlying pathologies. 
 
EP literature so far has been very confusing. As one can see from this study there are 
no consensus based criteria for demyelination and also the evidence for using specific 
cut offs are also lacking. However if we were to identify specific antibodies associated 
with specific EP abnormality, EP may hold a key for better understanding of this 
otherwise heterogeneous disorder. Moreover, if we identify that different EP patterns 
associated with different treatment response then performing early study may be 
beneficial for therapeutic decision-making and also for predicting prognosis. 
 
 
 
5.6 Conclusion: 
 
Our study highlights the pivotal role of EPS in identification and understanding of 
underlying GBS pathology. Existing EP criteria has various limitations and are not 
sufficient to achieve final EP diagnosis especially applied early in the course of GBS. 
Based on the result of this study, also in absence of a gold standard for diagnosis of EP 
subtype, I recommend using Rajabally criteria for future research analysis as well as  
in the wider clinical practice for early identification of final EP subtypes.  
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Chapter 6  
Outcome predictors and 
Validation of existing 
prognostic models- 
EGOS and mEGOS   
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6.1 Introduction 
 
 
 
Clinician’s ability to predict the outcome plays a crucial role in deciding treatment and 
also having this information early in the disease course may be vitally important for 
patients and their relatives so that they can make educated choices about their own 
treatment. GBS is a monophasic illness and although about 80 % of GBS patients 
make good functional recovery, about 20 % remain significantly disabled after 12 
months, and about 30 % require mechanical ventilation (MV), which in self is a bad 
prognostic marker and therefore identification of early prognostic factors that predict 
long term recovery and requirement of MV, has remained a major focus of GBS 
research. Identification of prognostic factors is critical in identifying patients who 
require closer monitoring in acute phase and also help clinicians to identify patients 
with poor prognosis, who may benefit from expensive and potentially dangerous 
immunomodulatory treatment which otherwise may not be necessary in patients with 
good prognosis. This chapter describes various clinical, EPS and biological prognostic 
factors and this is followed by detailed description of the methodology used to probe 
UK IGOS database to validate existing prognostic models. We also discuss the 
drawbacks of existing models and make suggestions at the end for further 
improvement of these models. 
 
6.2 Overview 
 
Early reports can be traced back to 1960, when Osler and Siddell, first claimed that 
raised CSF white cell count in GBS carried poor prognosis however subsequent 
studies did not substantiate this claim. (39,46,78) McLeod et al suggested that 
appearance of denervation on needle EMG did not carry favourable prognosis.(117) 
Similarly, some early reports suggested severe weakness involving all four limbs in 
acute phase of the disease also did not carry a favourable prognosis. (78,121,122) 
 
In 1988, Winer et al conducted first ever well designed prospective observational study 
of 100 GBS patients and found that time taken to become bed bound, requirement of 
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MV, age greater than 40 years and small or absent median nerve CMAP were 
associated with poor prognosis at 12 months. (39) 
 
As clinical trials continued to show beneficial effect of IVIG and PE on overall 
outcome of the disease, further clinical, EPS and biological factors were identified. 
 
6.2.1 Clinical predictors for long term outcome: 
 
 
 
Analysis of American GBS clinical trial data comparing PE with control, showed older 
age (>60 years), speed of onset of weakness (less than 7 days) and requirement of MV 
were associated with poor prognosis at 6 months. (83) Treatment with PE itself was 
proven to be a very significantly good prognostic factor in the study. Similar analysis 
performed on the data from The PE/Sandoglobulin trial, showed preceding diarrhoea, 
severe arm weakness and age > 50 were associated with poor 12 months prognosis 
defined by inability walk independently or death. (123) 
 
6.2.2 Electrophysiological Predictors of long term Outcome: 
 
 
 
EPS, when abnormal, plays very crucial role in diagnosis of GBS. It also helps with 
categorising GBS in to various EPS subtypes. Role of EPS in prognosis has been well 
described. McLeod et al first described that presence of denervation on needle EMG 
was associated with incomplete recovery.(117) The American PE clinical trial data 
showed mean distal CMAP of < 20 % of lower limit of normal was the most powerful 
predictor of poor outcome.(83) PE/Sandoglobulin trial performed in 2001, showed 
inexcitable nerves on EPS was associated with poor outcome at 12 months. (123) 
Outcome was similar in axonal and demyelinating forms of GBS. 
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6.2.3 Biological predictors of outcome: 
 
 
6.2.3.1 Immunological factors: 
 
 
 
GBS is an immunological disorder. While some factors such as level of 
immunological tolerance, level of complement activation and regulation and types of 
auto antibodies influence the disease expression; factors like anti-glycolipid 
antibodies, auto antibodies subtypes and response to IVIg may influence the overall 
outcome of the disease. 
 
Antibodies against GM1, GM1b, GD1a and GalNAc GD1a antigens are closely 
associated with AMAN subtype. Prognostic role of anti GM1 antibodies is widely 
debated. Bech at al showed that patients with short lasting elevation of anti GM1 IgG 
antibodies levels had faster recovery and long lasting elevation had poor recovery 
suggesting that monitoring of anti GM1 may predict the outcome. (126) In an another 
similar study Koga et el showed that the IgG1 subclass of anti-GM1 antibody is a 
major subtype indicative of slow recovery, whereas isolated elevation of IgG3 subclass 
antibody titre suggests rapid recovery and the variation in subclass pattern may depend 
on the pathogens precipitating GBS.(127) Recently Lardon et al demonstrated that fine 
specificity of IgG anti GM1 antibodies is associated with disease severity. (128) 
 
Since its first description in 2004, serum antibodies reacting against anti ganglioside 
complexes (GSC), made up of two different gangliosides but not to a single 
ganglioside, anti GSC antibodies have generated a huge interest in this field of 
biomarker research.(61) Kaida et al showed that patients with Anti–GD1a/GD1b 
complex antibody positive patients with GBS tend to have severe disabilities and 
cranial nerve deficits. (63) 
 
IVIg is a proven effective treatment for GBS. Most GBS patients receive standard dose 
of 2 gm/kg. Despite its efficacy, about 20% of the patients still remain unable to walk 
unaided after 6 months. Mechanism through which IVIG works in most immune 
mediated disorders remains complex. Similarly, the question of why some GBS 
patients respond to IVIg and others have partial response remained unanswered. It may 
120 
 
be pharmacokinetics of IVIg have a role to play and in first ever such attempt 
Kuitwaard et al performed a retrospective study of 174 GBS patients and showed that 
patients with a minor increase of serum IgG level after standard single IVIg dose had 
considerably slower recovery suggesting that those patients who metabolise IVIG 
quickly, do not respond favourably and may benefit by additional dose of IVIG. (129) 
However, this finding needs to be substantiated by a large study in order for it to be 
used in routine clinical practice. 
 
 
 
6.2.3.2 CSF markers of axonal damage: 
 
 
 
There is evidence to suggest that axonal damage especially in the acute phase of the 
disease adversely affects the long-term outcome. (132) The extent of axonal damage 
can be assessed by electrophysiological studies however, results may be inconclusive 
in the early phase of the disease, indicating the need for additional early markers of the 
axonal degeneration. A prospective study performed on 38 GBS patients, Petzold and 
colleagues showed that high CSF Neurofilaments (NFHs) levels at admission in GBS 
patients were associated with poor outcome indicating that NFHs, a biomarker for 
axonal damage were of prognostic value in GBS. (131) In this study patients with 
neurophysiological evidence of axonal damage had higher CSF NFHs levels compare 
to those with demyelinating GBS. This information is very helpful in the GBS, which 
has highly variable clinical course, and these biomarkers could be used in the early 
phase of the disease to identify those who would require more intensive forms of 
treatment. Besides axonal proteins like NF, detection of some glial proteins in the CSF 
of GBS patients may have prognostic roles. Jin et al analysed CSF samples of 26 GBS 
patients, studying CSF tau protein and compared the outcomes of these patients at 6 
months time. (132) The authors showed that CSF tau protein concentrations were 
significantly high in patients with poor prognosis. Similarly elevated levels of CSF 
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glial fibrillary acidic protein (GFAP) and S100 have been described in GBS patients 
however these observations have not been studied to provide any conclusion about 
their prognostic roles. 
 
6.2.4 Genetic factors: 
 
 
 
Genetic factors are widely recognised to be associated with increased host 
susceptibility in various inflammatory disorders. GBS is a heterogeneous disorder and 
reports of familial GBS and recurrent GBS in the same patient coupled with the 
observation that not all patients with the same preceding infection develop clinical 
GBS suggest that host susceptibility factors play a crucial role in development of 
GBS.(131) However, recent studies have failed to show such relationship between 
susceptibility of GBS and certain HLA class II alleles or CD1 gene 
polymorphisms.(132) With regard to prognosis, some immunoregulatory genes have 
been shown to influence the inflammatory response and thereby influence the 
prognosis. Recently some studies have showed that single-nucleotide polymorphisms 
of genes encoding Fcã-receptor-III, matrix metalloproteinase-9, and tumour necrosis 
factor-á and mannose-binding lectin are associated with the severity of GBS. (77) 
 
6.3 Development of GBS clinical Prognostic models: 
 
As shown in previous section, based on various clinical trials, variety of clinical, 
biological and EP predictors have been identified for GBS outcome. One of the key 
factors in development of any predictive prognostic model is the easy availability of 
predictive factors and in that respect, a model developed based on easily available 
clinical information is desirable. Biological factors may show strong correlation with 
poor outcome availability of laboratory tests may not be universal and even it is 
available it may take some time to get the results back. Similarly EP can be normal in 
early phase of GBS and therefore may not provide any useful prognostic information, 
when the urgent decision of treatments to be made in clinical settings. 
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Attempts have been made to develop such clinical prognostic models for GBS 
outcome. In an analysis performed on 388 GBS patients from two randomised 
controlled trial and one pilot study, Van Koningsveld et al found that age, preceding 
diarrhoea, and GBS disability score at 2 weeks, were the main predictors of poor 
outcome at 6 months. (135) Based on this analysis the authors have proposed a clinical 
prognostic model of GBS called EGOS. EGOS accurately predict the prognosis at 6 
months. However, one of the limitations of EGOS is that it cannot be applied earlier 
than two weeks of hospital admission. Early identification of patients with poor 
prognosis is very important in early therapeutic decision making as in the early phase, 
treatment is considered to be more effective and the chances of nerve regeneration are 
maximum.  
 
Walgaard et al subsequently produced a modified version of above model called 
mEGOS which can be used at the time of hospital admission and 1 week after the 
admission to predict the outcomes at 4, 12 and 26 weeks post admission.(136) One of 
the limitations of mEGOS model is its limited applicability to western world 
population, as the model was developed and validated on European patients and 
therefore may not be applicable to all other GBS patients with different demographic 
background.  
 
In this section, I have attempted to validate both clinical predictive models using IGOS 
UK data. 
 
6.4 Aims: 
 
One of the many aims of international GBS Outcome Study was to validate existing 
clinical prognostic models. We probed our IGOS UK database 
 
1. To validate EGOS model at two weeks 
 
2. To validate mEGOS model at admission 
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6.5 Methods: 
 
Validation of EGOS model: We first analysed data to identify patients who had their 6 
months outcome recorded. EGOS model predicts the patient’s ability to walk at 6 
months based on acute phase data of GBS disability scores at 2 weeks post entry into 
the study, preceding diarrhoea and age of the patient. The score ranges from 1 to 7, 
with three categories for age, two for diarrhoea and five categories for GBSD. Based 
on this model, prediction of inability to walk independently at 6 months ranges from 2 
to 83 %. We first calculated EGOS score of all our patients at 2 weeks post study entry 
and based on their EGOS values, predicted probabilities were calculated using EGOS 
statistical model 1/(1+exp[8.2-1.4*EGOS]). External validation was carried out using 
calibration and discrimination technique. For calibration predicted probabilities and 
observed probabilities were compared and plotted graphically on the table. For the 
model discrimination area under the curve (AUC) was calculated. 
 
Validation of mEGOS model at 7 days post admission: We first analysed data to 
identify patients who had their 6 months outcome recorded. mEGOS model predicts 
the patient’s ability to walk independently at 6 months based on acute phase data of 
MRC sum scores, preceding diarrhoea and age of the patient. mEGOS can be used at 
the time of admission however performance of this model was best at 7 days post 
admission and therefore we analysed 7 days post admission model in our study. 
MEGOS score ranges from 1 to 12, with three categories for age, two for diarrhoea 
and four categories for MRC sum score at 7 days post admission. Based on this model,  
prediction of inability to walk independently at 6 months ranges from 0 to 66 %. We 
first calculated mEGOS score of all our patients at 7 days post admission and based on 
their mEGOS, predicted probabilities were calculated using statistical model 
1/(1+exp[-4.5681 + (0.4364*mEGOS) ]). External validation was carried out using 
calibration and discrimination technique. For calibration predicted probabilities and 
observed probabilities were compared and plotted graphically on the table. For the 
model discrimination area under the curve (AUC) was calculated. Statistical 
calculations were performed using SPSS v 21. 
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6.6. Results: 
 
Validation of EGOS model: 
 
Out of 114 IGOS UK patients, outcome data available was available in 72 patients. 
 
 
                                 Table 6-1 Erasmus GBS Outcome Score 
  
 Categories Score 
  
   
 Age at onset (years)  > 60 1 
     
   41-60 0.5 
     
   < 41 0 
     
 Diarrhoea  Absence 0 
     
   Presence 1 
     
 GBS disability score  0-1 1 
     
   2 2 
     
   3 3 
     
   4 4 
     
   5 5 
     
 The Erasmus GBS Outcome Score   
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 Table 6-2 Percentage of patients who were unable to walk independently at   6 months in 
the derivation set and validation set as per EGOS score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As described, in the table 6.2,   EGOS model calibrated well in IGOS UK cohort. For 
calibration purpose we compared the frequency of outcome in four different EGOS 
score categories. In the score category 1-3, only 0.5 % patients of derivation set had 
EGOS Predicted  Observed 
1-3 0 % 0 % 
3.5-4.5 6.6 % 8.6 % 
5 20 % 15 % 
5.5-7 60 % 63 % 
Figure 6-1 Predicted probability of inability to walk at 6 months based on 
EGOS score 
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poor outcome as defined by inability to walk independently at 6 months’ time, in 
IGOS UK validation cohort none of our patient in that category had poor outcome. In 
the score category 3.5-4.5, only 7 % patients of derivation set had poor outcome as 
opposed to 8.6 %in our validation cohort. In the score category 5, 27 % patients of 
derivation set had poor outcome as opposed to 15 % in our validation cohort. 
Frequency in this group showed statistical significant variation ( P 0.02). In the score 
category 5.5-7, 52 % patients of derivation set had poor outcome as oppose to 63 % in 
our validation cohort. 
 
We then analysed discriminatory capacity (figure 6.2) of EGOS model in IGOS UK 
cohort. AUC for prediction of outcome at 6 months using EGOS model was 0.87 
suggestive of very good discriminatory power of this model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 6-2 Area Under Curve (AUC) of EGOS model 
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Validation of mEGOS model at 7 days post admission:  
  
 
Table 6-3 Modified Erasmus GBS Outcome Score Model 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Categories  Score 
    
Age at onset (years) > 60  2 
    
 41-60  1 
    
 < 41  0 
    
Diarrhoea Absence  0 
    
 Presence  1 
    
MRC sum score at 7 days 51-60  0 
post admission    
 41-50  3 
    
 31-40  6 
    
 0-30  9 
    
MEGOS   0-12 
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              Table 0-4 Percentage of patients who were unable to walk independently at    
               6 months in the derivation set and validation set as per EGOS score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           Figure 6.4 AUC of mEGOS model 
 
mEGOS at 7 days post admission Predicted (%) Observed(%) 
1 to 5 0 2.9 
6 t0 7 15 18 
8 to 9 30 16 
10 to 12 55 53 
Figure 6-3 Predicted probability of patient being unable to walk independently at 6 
months Vs mEGOS at 7 days post admission 
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As shown in table 6.3, mEGOS model calibrated well in IGOS UK dataset. There was 
no significant difference in observed and predicted frequencies of patient unable to walk 
at 6 months using mEGOS model. Similarly, AUC (Figure 6.4) for mEGOS model was 
0.84 in IGOS UK cohort, suggestive of very good discriminatory power of this model 
 
6.7 Discussion: 
 
Prediction of prognosis is an essential part of clinical practice. In context of GBS, which 
is a heterogeneous disorder, it even becomes more important. While general prognostic 
information has been available for long time, prediction of prognosis of individual GBS 
cases has not been available. In first ever such attempt Koningsveld et al have developed 
a clinical prognostic model based on multivariate regression analysis of the clinical data 
available from 388 GBS patients who participated in two different clinical trials. EGOS 
model is based on simple clinical information such as age of the patient, preceding 
diarrhoea and disability at 2 weeks post entry into study. The model predicts individual 
patient’s ability to walk unaided at 6 months’ time. The predicted probabilities ranged 
from 2 to 82 %. 
 
As shown in the result EGOS model performed well on our IGOS UK database. 
Observed probabilities in IGOS UK cohort agreed well with predicted probabilities of 
the model. Also model showed very good discriminatory capacity based on AUC of 
0.87.These results show that EGOS can be extremely helpful in providing clinical 
prognostic information in acute phase of the disease. However one of the issues with 
EGOS model is that it can only be applied after 2 weeks of entry into clinical study. 
Most patients received treatment in first two weeks of time and therefore this model may 
not be clinically helpful in order to make early treatment decisions on patients. 
 
 
130 
 
In order to mitigate this problem, Walgaard et al proposed another model called 
mEGOS, which was based on clinical information such as age, preceding diarrhoea 
and MRC sum score at the time of admission and 7 days post admission. This model 
was essentially based on the same clinical database that was used for the development 
of EGOS model. MEGOS predicts patient’s ability to walk unaided at 6 months. This 
model can be applied at two time points 1) at the time of admission and 2) 7 days post 
admission. The model performed very well at 7 days post admission compared to at 
the time of admission and therefore we applied this model to IGOS UK cohort using 7 
days post admission clinical information. When applied to IGOS UK database, 
mEGOS model showed excellent discriminatory capacity with AUC of 0.84. 
 
 
 
Overall the results of this study provide proof of principle that prognostic model like 
EGOS and mEGOS can be applied to GBS patients with different geographical area. 
One of the important requirements of prognostic model is that it should be useful and 
readily applicable in most clinical settings. MEGOS model uses MRC sum score 
available on admission and 7 days post admission to hospital to predict the 6 month 
outcome. This may have several limitations 1) timing of hospital admission depends 
on various factors such as availability of local medical services, this especially a major 
drawback in developing country as often patients do not get admitted to local hospitals 
until late in the disease course due to lack of finances or resources. 2) Using MRC sum 
score may be difficult for non neurologist physicians for example in the UK, most 
patients will first get admitted to district general hospital and performing MRC sum 
score can be difficult by non neurologist physicians 3) some patients with pure sensory 
GBS or MFS-GBS variants may not have weakness and in those patients MRC sum 
score would be normal, despite patient being significantly disabled. 
 
In order to address above limitation we propose two modifications to the model 1) 
Along with factors like age and diarrhoea, model should use a parameter, which can 
be easily collected by any medical physicians without much neurological training. In 
this respect, I propose the future model should be designed using GBSD scale, which 
captures the disability very well irrespective of type of GBS 2) Timing of the 
collection of acute phase data should be standardized and we propose to use date of 
onset of symptoms as a reference point rather than admission date as date of onset of 
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symptoms will likely to remain constant irrespective of country of practice and 
therefore model will be applicable to wider geographical population. IGOS provides a 
unique opportunity to refine existing models. In IGOS most patients are recruited 
within 2 weeks of onset of symptoms and therefore two separate models can be 
developed on the patients who have been recruited in the first week of symptoms onset 
and second week of onset of symptoms. Also besides using “ ability to walk unaided” 
as a standard outcome, future analysis of complete IGOS dataset should use other 
outcome scales like RODS, which will potentially increase the statistical power of the 
model due to  linearity of the scale. Similarly, electrophysiological date could be 
included in the model; however factors such as lack of standardisation in performing 
EPS and delay in development of EP abnormality in some GBS patients will have to 
be considered very carefully before their inclusion in to prognostic models. 
 
6.8 Conclusion: 
 
Above results provide the proof of the concept that predictive models like EGOS and 
mEGOS can be useful in providing important prognostic information to GBS patients 
early in the course when the treatment decisions are critical. However there are certain 
limitations to these models and future models can be developed based on keeping 
these limitations in mind so that it can be applicable to wider geographical 
populations. This is important especially in the counties with limited resources where 
the aim is to direct the resources in appropriate direction using these prognostic 
models 
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Chapter 7 Conclusions 
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IGOS represents the first international prospective observational study with an aim to 
study 1000 GBS patients around the world. It provides a unique opportunity to study 
various clinical, EP, serological and genetic factors in relation to outcomes in a wider 
geographical population. 
 
As part of this thesis, we analysed the data from 114 patients from UK. We compared 
our outcomes with previous observational studies. The study shows that IVIG is now 
widely available and most commonly (90 % of total GBS patients) administered 
treatment in GBS patients in the UK. One of the interesting findings of our study is the 
patients with mild GBS (GBSD < 2) are also being treated with immunotherapy, 
without any significant long-term benefit. If this finding is validated with larger IGOS 
cohort this practice should be discouraged. 
 
Despite wider availability of immunotherapy, GBS outcomes have not changed over 
the past 20 years. In our study, 5.1 % patients died, 18 % required mechanical 
ventilation, 15 % patients remain unable to walk at 12 months and only 22 % patients 
had complete neurological recovery at 12 months. These results highlight urgent need 
of more effective immunotherapies in these patients. 
 
However, due to rarity of this condition, conducting multi centred RCT can be 
expensive and challenging and in these circumstances IGOS can provide an excellent 
historical outcome database to which newer therapies can be tested against. Also 
development of reliable prognostic models not only help patients and clinicians to 
guide the treatment decisions but also these models can be used early in the disease 
course to identify patients with poor prognosis, when the newer treatments can be 
more effective. In our study I validated existing prognostic models like EGOS and 
mEGOS. Our study shows that these models can help identifying and stratifying 
patients with poor prognosis,  however , some refinement into these models required 
for their wider geographical applicability. This issue can be addressed by analysing 
large IGOS database. 
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In our study we also tried to address some electrodiagnostic issues related to GBS. Our 
study shows that currently available EP criteria are not sensitive enough to identify 
various EP subtypes. Some authors have suggested performing two sets of EPS, in 
order to achieve correct EP diagnosis. However performing two sets of EP can be 
challenging in resource poor countries. Rajabally et al suggested modified criteria, 
which probably mitigates the need of two EPS. In our study we probed this criteria and 
showed comparable results. However this finding needs to validate by larger EP 
database and IGOS will provide that unique opportunity to do so. 
              
             Future directions: 
 
 
Identification of new target antigens and development of new diagnostic 
biomarkers of GBS: 
 
One of the major focuses of biomarker development in GBS is identification and 
characterization of anti-glycolipid antibodies. Antibodies against glycolipids, 
especially against various gangliosides are present in about 60% of the GBS patients in 
acute phase. More than 20 different anti-glycolipid antibody specificities have been 
shown to be associated with GBS so far. Furthermore the recent discovery of anti-
glycolipid complex (GSC) antibodies that react with two different gangliosides 
structures in heteromeric complex has not only given a new dimension but also added 
more complexities to this area of research. Thus, from 20 single glycolipids, 190 1:1 
complexes can be generated and if 3 or 4 glycolipids are combined, the number of 
complexes increases significantly which makes current low throughput ELISA 
screening techniques practically impossible in terms of time required to prepare the 
reagents and consumption of the reagents. Therefore, the Willison group has recently 
developed a novel miniaturized method called combinatorial glycoarray for assessing 
sera for anti-GSC antibodies. In this respect, IGOS will provide an excellent 
opportunity to screen GBS sera for anti GSC antibodies and also for antibodies against 
novel axo-glial proteins. 
 
Development of consensus based EP criteria: 
 
Work described in thesis highlights some important drawbacks of existing EP criteria. 
The current EP criteria do not consider the possibility of axonal conduction block and 
also the nodo-paranodopathies in axonal GBS and as a result some patients can be 
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wrongly classified to have AIDP. Correct EP classification is of paramount importance 
for correct serological and EP correlation. Systematically collected IGOS EP database 
will help study various factors responsible for these drawbacks and will help develop a 
universal consensus based EP diagnostic criteria. 
 
Validation of existing prognostic models of GBS: 
 
Work described in this thesis provides further proof of the concept that prognostic 
model help stratifying patients with poor prognosis early in the disease course. IGOS 
database will help validate these models in wider geographical population and if found 
to have good discriminatory capacity, will have potential to be used in routine clinical 
practice. 
 
 
IGOS-2 
 
As part of IGOS study, more than 1000 GBS patients have been recruited worldwide. 
For a relatively rare disease like GBS, this is a remarkable achievement by 
Inflammatory Neuropathy Consortium. However one of the major issues in a multi 
cantered observational study like IGOS is data quality and missing data. These factors 
can have significant impact on statistical power of the study. IGOS will provide a 
better insight in to the factors leading to data quality compromise and missing data; 
once these factors are identified future observational study can be designed to 
minimize the missing data and to improve the quality of the data. 
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